CA2203033C - Compounds and compositions for delivering active agents - Google Patents
Compounds and compositions for delivering active agents Download PDFInfo
- Publication number
- CA2203033C CA2203033C CA002203033A CA2203033A CA2203033C CA 2203033 C CA2203033 C CA 2203033C CA 002203033 A CA002203033 A CA 002203033A CA 2203033 A CA2203033 A CA 2203033A CA 2203033 C CA2203033 C CA 2203033C
- Authority
- CA
- Canada
- Prior art keywords
- active agent
- composition
- compound
- biologically
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
Abstract
Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Description
COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
FIELD OF THE INVENTION
The present invention relates to compounds for delivering active agents, and particularly biologically active agents such as, for example, - bioactive peptides and the like. These compounds are used as carriers to facilitate the delivery of a cargo to a target. The carriers are modified amino acids and are well suited to form non-covalent mixtures with biologically-active agents for oral administration to animals. Methods for the preparation and for the administration of such compositions are also disclosed.
BACKGROUND OF THE INVENTION
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through whrch delivery occurs, the environment of the target for delivery, or the target itself.
Biologically active agents are particularly vulnerable to such barriers. For example in the delivery to animals of pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH
variations, lipid bi-layers, and degrading enzymes.
These barriers are of particular significance in the design of oral delivery systems. Oral delivery of many biologically active agents would be the route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal (GI) tract, powerful digestive enzymes, and active agent impermeable gastro-intestinal membranes.
Among the numerous agents which are not typically amenable to oral administration are biologically active peptides, such as calcitonin and insulin;
polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, or the like.
Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.
Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel et al.
(1976), FEBS Letters, Vol. 62, pg. 60; and Hashimoto et al. (1979), Endocrinology Japan, Vol. 26, pg. 337.
However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life;
(4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.
More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.
FIELD OF THE INVENTION
The present invention relates to compounds for delivering active agents, and particularly biologically active agents such as, for example, - bioactive peptides and the like. These compounds are used as carriers to facilitate the delivery of a cargo to a target. The carriers are modified amino acids and are well suited to form non-covalent mixtures with biologically-active agents for oral administration to animals. Methods for the preparation and for the administration of such compositions are also disclosed.
BACKGROUND OF THE INVENTION
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through whrch delivery occurs, the environment of the target for delivery, or the target itself.
Biologically active agents are particularly vulnerable to such barriers. For example in the delivery to animals of pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH
variations, lipid bi-layers, and degrading enzymes.
These barriers are of particular significance in the design of oral delivery systems. Oral delivery of many biologically active agents would be the route of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal (GI) tract, powerful digestive enzymes, and active agent impermeable gastro-intestinal membranes.
Among the numerous agents which are not typically amenable to oral administration are biologically active peptides, such as calcitonin and insulin;
polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, or the like.
Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.
Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel et al.
(1976), FEBS Letters, Vol. 62, pg. 60; and Hashimoto et al. (1979), Endocrinology Japan, Vol. 26, pg. 337.
However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life;
(4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.
More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.
There is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents.
SUMMARY OF THE INVENTION
Compounds useful in the delivery of active agents are provided.
These compounds include O / I H
HO \ O
O H I \ II
HO \ O /
O / / III
HO \ 0 cl O / H IV
\ I 0 F
HO
OH
I / V
O / I H
SUMMARY OF THE INVENTION
Compounds useful in the delivery of active agents are provided.
These compounds include O / I H
HO \ O
O H I \ II
HO \ O /
O / / III
HO \ 0 cl O / H IV
\ I 0 F
HO
OH
I / V
O / I H
Vf O
OH
HO
VII
O H
\ 0 H
O H VIII
O
H
O / I H= IX
\ \
HO
A / I H / I x \ O \
H
F
F XI
O / I H
= OH
H
p Xil , 5 \ O
H
p H XIII
O
H
/ ~
HO O \ XIV
YO, O
p / H II / XV
\ O F
HO
p / iH
\ I ~J(1 XVI
OC
HO
O / I H
\ p XVII
HO
XVill O ~ H O \ .
HO \
-O H
ixCj O N XX
\ I O F
HO
F
XXI
O H II
I 1 y O
H
O / I H XXII
HO \ ~
OH
O H
HO XXIII
O ~ H XXIV
H \ O
F
0 ~ I H
HO ~ (JL XXV
O H
HO O XXVI
O ~ I H
H ~ (IIIJ XXVII
N)ro H
iiIIIIj XXIX
O ~ H
\ I 0 XXX
H
N-ya ~O ~ I H
XXXI
HO =
O H
HO OH XXXII
O
OH
N
H 0 xxxiii N
~ H
HO \ I O
O XXXI V
\
N I /
a H Y,, r HO O CI XXXV
9 j 0 / H
\ I ix1IIIJ XXXVI
HO
N
p H
HO
HO p XXXViiI
\ I ,~
H \ ~ p \ I XXXIX
H
O I \
HO \ I H
XL
I \
O / XLI
OH
HO
VII
O H
\ 0 H
O H VIII
O
H
O / I H= IX
\ \
HO
A / I H / I x \ O \
H
F
F XI
O / I H
= OH
H
p Xil , 5 \ O
H
p H XIII
O
H
/ ~
HO O \ XIV
YO, O
p / H II / XV
\ O F
HO
p / iH
\ I ~J(1 XVI
OC
HO
O / I H
\ p XVII
HO
XVill O ~ H O \ .
HO \
-O H
ixCj O N XX
\ I O F
HO
F
XXI
O H II
I 1 y O
H
O / I H XXII
HO \ ~
OH
O H
HO XXIII
O ~ H XXIV
H \ O
F
0 ~ I H
HO ~ (JL XXV
O H
HO O XXVI
O ~ I H
H ~ (IIIJ XXVII
N)ro H
iiIIIIj XXIX
O ~ H
\ I 0 XXX
H
N-ya ~O ~ I H
XXXI
HO =
O H
HO OH XXXII
O
OH
N
H 0 xxxiii N
~ H
HO \ I O
O XXXI V
\
N I /
a H Y,, r HO O CI XXXV
9 j 0 / H
\ I ix1IIIJ XXXVI
HO
N
p H
HO
HO p XXXViiI
\ I ,~
H \ ~ p \ I XXXIX
H
O I \
HO \ I H
XL
I \
O / XLI
O ci HO
NY
OH
N XLII
H O
\ O /
OH
H XLIII
O
HO O
OH
F
W
\ I XLIV
O ~ I H XLV
H \ O
or salts thereof.
Compositions comprising at least one biologically active agent and at least one of the compounds above are also provided. Further contemplated by the present invention are dosage unit forms that include these compositions.
Also contemplated is a method for preparing these compositions which comprises mixing at least one active agent with at least one compound as described above, and optionally, a dosing vehicle.
In an alternative embodiment, these non-toxic compounds are orally administered to animals as part of a delivery system by blending or mixing the compounds with an active agent prior to administration.
DETAILED DESCRIPTION OF THE INVENTION
The specific compounds of the present invention or salts thereof such as, for example, sodium salts, may be used to deliver various active agents through various biological, chemical, and physical barriers. These compounds are particularly suited for delivering active agents which are subject to environmental degradation. The compounds and compositions of the subject invention are particularly useful for delivering or administering biologically-active agents to any animals such as birds; mammals, such as primates and particularly humans; and insects.
Other advantages of the present invention include the use of easy to prepare, inexpensive raw materials. The compositions and the formulation methods of the present invention are cost effective, simple to perform, and amenable to industrial scale up for commercial production.
Amino acids, poly amino acids, and peptides, in modified form, may be used to deliver active agents including, but not limited to, biologically active agents such as for example, pharmacological and therapeutic agents.
An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids.
Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g. an ester, anhydride, or an anhydride linkage. Special mention is made of non-naturally occurring poly amino acids and particularly non-naturally occurring hetero poly amino acids, i.e. polymers of mixed amino acids.
Peptides are two or more amino acids joined by a peptide bond.
Peptides can vary in length from dipeptides with two amino acids to poly peptides with several hundred amino acids. See Chambers Biological Dictionary, editor Peter M. B. Walker, Cambridge, England: Chambers Cambridge, 1989, page 215. Special mention is made of di-peptides, tri-peptides, tetra-peptides, and penta-peptides.
The terms modified amino acids, modified poly amino acids, and modified peptides are meant to include amino acids which have been modified or poly amino acids and peptides in which at least one amino acid has been modified by acylating at least one free amine group with an acylating agent which reacts with at least one of the free amine groups present.
Modified Amino Acids Several of the compounds of the present invention are broadly represented by one of formula XLVI or XLVII below:
Ar-Y-(R')n-OH XLVI
wherein Ar is a substituted or unsubstituted phenyl or naphthyl;
(1 11 Y is - C- or -SO2-, R' has the formula -N(R3)-R2-C-, wherein:
RZ is C, to C24 alkyl, C, to C24 alkenyl, phenyl, naphthyl, (C, to Clo alkyl) phenyl, (C, to C,o alkenyl) phenyl, (C, to C,o alkyl) naphthyl, (C, to Clo alkenyl) naphthyl, phenyl (Cl to C,o alkyl), phenyl (C, to C,o alkenyl), naphthyl (C, to C,o alkyl), and naphthyl (C, to C,o alkenyl);
R2 is optionally substituted with C, to C4 alkyl, C, to C4 alkenyl, C, to C4 alkoxy, -OH, -SH and -C02R4 or any combination thereof;
R4 is hydrogen, C, to C4 alkyl or C, to C4 alkenyl;
R2 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and R3 is hydrogen, C, to C4 alkyl or C, to C4 alkenyl; or RS-OH XLVII
wherein: R5 is (i) C3-C,p cycloalkyl, optionally substituted with C,-C7 alkyl, C2-C7 alkenyl, C1-C7 alkoxy, hydroxy, phenyl, phenoxy or -C02R8, wherein R8 is hydrogen, C1-C4 alkyl, or C2-C4 alkenyl; or (ii) C,-C6 alkyl substituted with C3 C,o cycloalkyl;
R6 is hydrogen, C,-C4 alkyl, or C2-C4 alkenyl;
R' is C1-C24 alkyl, C2-C24 alkenyl, C3 C,o cycloalkyl, C3 C,o cycloalkenyl, phenyl, naphthyl, (C,-C,o alkyl) phenyl, (C2-C,o alkenyl) phenyl, (C,-C,o alkyl) naphthyl, (CZ C,o alkenyl) naphthyl, phenyl (C,-C,o alkyl), phenyl (C2 C,o alkenyl), naphthyl (C,-C,o alkyl) or naphthyl (CZ C,o alkenyl);
R' being optionally substituted with C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, -OH, -SH, -C02R9, C3-C,o cycloalkyl, C3 C,o cycloalkenyl, heterocycle having 3-10 ring atoms wherein the hetero atom is one or more of N, 0, S or any combination thereof, aryl, (C,-C,o alk)aryl, ar(C,-C,o alkyl), or any combination thereof;
R' being optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof; and R9 is hydrogen, C1-C4 alkyl, or C; C4 alkenyl.
Special mention is made of compounds I - XLV above.
The modified amino acids of formulae I-XLV may be prepared by reacting single amino acids, mixtures of two or more amino acids, amino acid esters, or amino acid amides, with an amine modifying agent which reacts with free amino moieties present in the amino acids to form amides.
Modified amino acids are typically prepared by modifying the amino acids or an ester thereof. Many of these compounds are prepared by acylation with acylating agents having the formula wherein: R10 is the appropriate radical to yield the modification indicated in the final product as would be within the skill of the art based upon the detailed disclosure herein, and Y is a leaving group. Typical leaving groups include, but are not limited to, halogens such as, for example, chlorine, bromine, and iodine.
Additionally, the corresponding anhydrides are suitable acylating agents.
Many of the compounds of the present invention can be readily prepared and modified by methods within the skill of those in the art based upon the present disclosure. For example, the modified amino acid compounds above may be prepared by reacting the single amino acid with the appropriate acylating agent or an amine modifying agent which reacts with free amino moiety present in the amino acids to form amides. Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art.
For example, the amino acid can be dissolved in aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide, and heated at a temperature ranging between about 5 C and about 70 C, preferably between about 10 C and about 40 C, for a period ranging between about 1 hour and about 4 hours, preferably about 2.5 hours. The amount of alkali employed per equivalent of NH2 groups in the amino acid generally ranges between about 1.25 and about 3 mmole, preferably between about 1.5 and about 2.25 mmole per equivalent of NH2. The pH of the solution generally ranges between about 8 and about 13, preferably ranging between about 10 and about 12.
Thereafter, the appropriate amino modifying agent is added to the amino acid solution while stirring. The temperature of the mixture is maintained at a temperature generally ranging between about 5 C and about 70 C, preferably between about 10 C and about 40 C, for a period ranging between about 1 and about 4 hours. The amount of amino modifying agent employed in relation to the quantity of amino acid is based on the moles of total free NH2 in the amino acid. In general, the amino modifying agent is employed in an amount ranging between about 0.5 and about 2.5 mole equivalents, preferably between about 0.75 and about 1.25 equivalents, per molar equivalent of total NH2 group in the amino acid.
The reaction is quenched by adjusting the pH of the mixture with 5 a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between about 2 and about 3. The mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate. The upper layer is discarded, and the modified amino acid is collected from the lower layer by filtration or decantation. The crude modified 10 amino acid is then dissolved in water at a pH ranging between about 9 and about 13, preferably between about 11 and about 13. Insoluble materials are removed by filtration and the filtrate is dried in vacuo. The yield of modified amino acid generally ranges between about 30 and about 60%, and usually about 45%.
15 If desired, amino acid esters, such as, for example methyl or ethyl esters of amino acid compounds, may be used to prepare the modified amino acids of the invention. The amino acid ester, dissolved in a suitable organic solvent such as dimethylformamide or pyridine, is reacted with the appropriate amino modifying agent at a temperature ranging between about 5 C and about 700C, preferably about 250C, for a period ranging between about 7 and about 24 hours. The amount of amino modifying agent used relative to the amino acid ester is the same as described above for amino acids.
Thereafter, the reaction solvent is removed under negative pressure and the ester functionality is removed by hydrolyzing the modified amino acid ester with a suitable alkaline solution, e.g. 1 N sodium hydroxide, at a temperature ranging between about 50 C and about 80 C, preferably about 70 C, for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group. The hydrolysis mixture is then cooled to room temperature and acidified, e.g. aqueous 25%
hydrochloric acid solution, to a pH ranging between about 2 and about 2.5. The modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.
The modified amino acid may be purified by recrystallization or by fractionation on solid column supports. Suitable recrystallization solvent systems include acetonitrile, methanol and tetrahydrofuran. Fractionation may be performed on a suitable solid column supports such as alumina, using methanol/n-propanol mixtures as the mobile phase; reverse phase column supports using trifluoroacetic acid/acetonitrile mixtures as the mobile phase;
and ion exchange chromatography using water as the mobile phase. When anion exchange chromatography is performed, preferably a subsequent 0-500 mM
sodium chloride gradient is employed.
Active Agents Active agents suitable for use in the present invention include biologically active agents, chemically active agents, including, but not limited to, fragrances, as well as other active agents such as, for example, cosmetics.
Biologically active agents include, but are not limited to, pesticides, pharmacological agents, and therapeutic agents. For example, biologically active agents suitable for use in the present invention include, but are not limited to, peptides, and particularly small peptides; hormones, and particularly hormones which by themselves do not or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; or any combination thereof. Further examples include, but are not limited to, human growth hormones; bovine growth hormones; growth releasing hormones; interferons; interleukin-n~
insulin;
heparin, and particularly low molecular weight heparin; calcitonin;
erythropoietin;
atrial naturetic factor; antigens; monoclonal antibodies; somatostatin;
adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin;
cromolyn sodium (sodium or disodium chromoglycate); vancomycin;
desferrioxamine (DFO); anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.
Delivery Systems The compositions of the present invention may include one or more active agents.
In one embodiment, compounds I-XLV or poly amino acids or peptides that include at least one of these compounds may be used directly as a drug delivery carrier by simply mixing one or more compound, poly amino acid or peptide with the active ingredient prior to administration.
In an alternative embodiment, the compounds, poly amino acids, or peptide may be used to form microspheres containing the active agent.
These compounds, poly amino acids, or peptides are particularly useful for the oral administration of certain biologically-active agents, e.g., small peptide hormones, which, by themselves, do not pass or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastrointestinal tract.
If the modified amino acids, poly amino acids, or peptides are to be converted into microspheres, the mixture is optionally heated to a temperature ranging between about 20 and about 50 C, preferably about 40 C, until the modified amino acid(s) dissolve. The final solution contains between from about 1 mg and to about 2000 mg of compound, poly amino acid, or peptide per mL
of solution, preferably between about 1 and about 500 mg per mL. The concentration of active agent in the final solution varies and is dependent on the required dosage for treatment. When necessary, the exact concentration can be determined by, for example, reverse phase HPLC analysis.
When the compounds, poly amino acids, or peptides are used to prepare microspheres, another useful procedure is as follows: Compounds, poly amino acids, or peptides are dissolved in deionized water at a concentration ranging between about 75 and about 200 mg/ml, preferably about 100 mg/ml at a temperature between about 25 C and about 60 C, preferably about 40 C.
Particulate matter remaining in the solution may be removed by conventional means such as filtration.
Thereafter, the compound, poly amino acid, or peptide solution, maintained at a temperature of about 40 C, is mixed 1:1 (V/V) with an aqueous acid solution (also at about 40 C) having an acid concentration ranging between about 0.05 N and about 2 N, preferably about 1.7 N. The resulting mixture is further incubated at 40 C for a period of time effective for microsphere formation, as observed by light microscopy. In practicing this invention, the preferred order of addition is to add the compound, poly amino acid, or peptide solution to the aqueous acid solution.
Suitable acids for microsphere formation include any acid which does not (a) adversely effect the modified amino acids, poly amino acids, or peptides e.g., initiate or propagate chemical decomposition;
(b) interfere with microsphere formation;
(c) interfere with microsphere incorporation of the cargo;
and (d) adversely interact with the cargo.
Preferred acids for use in this aspect include acetic acid, citric acid, hydrochloric acid, phosphoric acid, malic acid and maleic acid.
A microsphere stabilizing additive may be incorporated into the aqueous acid solution or into the compound or cargo solution prior to the microsphere formation process. With some drugs the presence of such additives promotes the stability and/or dispersibility of the microspheres in solution.
The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (w/v), preferably about 0.5 % (w/v).
Suitable, but non-limiting, examples of microsphere stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine.
The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
Under the above conditions, the compound molecules, poly amino acids, or peptides form hollow or solid matrix type microspheres wherein the cargo is distributed in a carrier matrix or capsule type microspheres encapsulating liquid or solid cargo. If the compound, poly amino acid, or peptide microspheres are formed in the presence of a soluble material, e.g., a pharmaceutical agent in the aforementioned aqueous acid solution, this material will be encapsulated within the microspheres. In this way, one can encapsulate pharmacologically active materials such as peptides, proteins, and polysaccharides as well as charged organic molecules, e.g., antimicrobial agents, which normally have poor bioavailability by the oral route. The amount of pharmaceutical agent which may be incorporated by the microsphere is dependent on a number of factors which include the concentration of agent in the solution, as well as the affinity of the cargo for the carrier. The compound, poly amino acid, or peptide microspheres do not alter the physiological and biological properties of the active agent. Furthermore, the encapsulation process does not alter the pharmacological properties of the active agent. Any pharmacological agent can be incorporated within the microspheres. The system is particularly advantageous for delivering chemical or biological agents which otherwise would be destroyed or rendered less effective by conditions encountered within the body of the animal to which it is administered, before the microsphere reaches its target zone (i. e., the area in which the contents of the microsphere are to be released) and for delivering pharmacological agents which are poorly absorbed in the gastro-intestinal tract. The target zones can vary depending upon the drug employed.
The particle size of the microsphere plays an important role in determining release of the active agent in the targeted area of the gastro-intestinal tract. The preferred microspheres have diameters between about <
0.1 microns and about 10 microns, preferably between about 0.5 microns and about 5 microns. The microspheres are sufficiently small to release effectively the active agent at the targeted area within the gastro-intestinal tract such as, for example, between the stomach and the jejunum. Small microspheres can also be administered parenterally by being suspended in an appropriate carrier fluid (e.g., isotonic saline) and injected directly into the circulatory system, intramuscularly or subcutaneously. The mode of administration selected will vary, of course, depending upon the requirement of the active agent being administered. Large amino acid microspheres (>50 microns) tend to be less effective as oral delivery systems.
The size of the microspheres formed by contacting compounds, poly amino acids, or peptides with water or an aqueous solution containing active agents can be controlled by manipulating a variety of physical or chemical parameters, such as the pH, osmolarity or ionic strength of the encapsulating solution, size of the ions in solution and by the choice of acid used in the encapsulating process.
The administration mixtures are prepared by mixing an aqueous solution of the carrier with an aqueous solution of the active ingredient, just prior to administration. Alternatively, the carrier and the biologically active ingredient can be admixed during the manufacturing process. The solutions may 5 optionally contain additives such as phosphate buffer salts, citric acid, acetic acid, gelatin and gum acacia.
. Stabilizing additives may be incorporated into the carrier solution.
With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.
10 The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (W/V), preferably about 0.5 % (W/V).
Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
15 The amount of active agent is an amount effective to accomplish the purpose of the particular active agent. The amount in the composition typically is a pharmacologically or biologically effective amount. However, the amount can be less than a pharmacologically or biologically effective amount when the composition is used in a dosage unit form, such as a capsule, a tablet 20 or a liquid, because the dosage unit form may contain a multiplicity of carrier/biologically active agent compositions or may contain a divided pharmacologically or biologically effective amount. The total effective amounts can then be administered in cumulative units containing, in total, pharmacologically or biologically active amounts of biologically or pharmacologically active agent.
The total amount of active agent, and particularly biologically active agent, to be used can be determined by those skilled in the art. However, it has surprisingly been found that with some biologically active agents, the use of the presently disclosed carriers provides extremely efficient delivery. Therefore, lower amounts of biologically active agent than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and therapeutic effects.
The amount of carrier in the present composition is a delivery effective amount and can be determined for any particular carrier or biologically active agent by methods known to those skilled in the art.
Dosage unit forms can also include any of excipients; diluents;
disintegrants; lubricants; plasticizers; colorants; and dosing vehicles, including, but not limited to water, 1,2-propane diol, ethanol, olive oil, or any combination thereof.
Administration of the present compositions or dosage unit forms preferably is oral o.r by intraduodenal injection.
The delivery compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof.
These compounds have the formulas below:
Me-,Me Y O
NHOH
~
HO/ O H O
XLIX
Me Actinonin Me' Me Y O
NHOH
O H k 0 HO
Me L
Epiactnonin Derivatives of these compounds are disclosed in U.S. Patent No. 5,206,384.
Actinonin derivatives have the formula:
O
I I
R~r-C
~CH2 H 0 LI
N
O CH
CH3 \CH3 R71 wherein R12 is sulfoxymethyl or carboxyl or a substituted carboxy group selected from carboxamide, hydroxyaminocarbonyl and alkoxycarbonyl groups; and R13 is hydroxyl, alkoxy, hydroxyamino or sulfoxyamino group. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.
The compounds and compositions of the subject invention are useful for administering biologically active agents to any animals such as birds;
mammals, such as primates and particularly humans; and insects. The system is particularly advantageous for delivering chemically or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the active agent its target zone (i.e. the area in which the active agent of the delivery composition are to be released) and within the body of the animal to which they are administered. Particularly, the compounds and compositions of the present invention are useful in orally administering active agents, especially those which are not ordinarily orally deliverable.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples illustrate the invention without limitation.
Example 1 Compound VI was prepared as follows:
Acetylsalicyloyl chloride (47.00 g, 0.24 mol, 1 equiv.) was added portionwise to a mixture of 4-(4-aminophenyl)butyric acid (50.OOg, 0.28 mol, 1.2 equiv.) in aqueous sodium hydroxide (2M, 300 mL). The reaction was stirred at 25 C for 2 hours, and the resultant solution was acidified with aqueous hydrochloric acid (1 M) to pH 2.1. The resultant precipitate was filtered, and was washed with aqueous hydrochloric acid (1 M, 3 x 100 mL) and water to give Compound VI as a pale pink solid (31.89 g, 52%).
Properties are listed below.
'H NMR (300 MHz, DMSO-ds) 6: 7.74 (1H, dd), 7.38 (2H, d), 7.21 (3H, m), 6.67 (1 H, m), 6.57 (1 H, m), 2.48 (2H, t), 2.07 (2H, t), 1.71 (2H, m). Anal. Calcd for C17H17NO4: C, 68.20; H, 5.73;
N, 4.70. Found: C, 68.22; H, 5.61; N, 4.66.
Similar procedures were used to prepare Compounds II, V, X, XIV, XVIII, XXII, XXV, XXVI, XXVIi, XXVIII, XXIX, XXX, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XL, XLI, XLII, and XLV.
Properties are listed below.' Compound II -'H NMR (300MHz, D20): 6 7.23(9H, m), 3.62(2H, s), 2.50(2H, t), 2.17(2H, t), 1.73(2H, q) Compound V - Anal. Calcd for C17H17NO5: C, 64.74, H, 5.45, N, 4.44 Found:
C, 64.11, H, 5.46, N, 4.21. 'H NMR (300MHz, D20): 6 7.6 (1H,d), 7.35 (2H,d), 7.15 (2H,m), 6.05 (1 H,d), 2.5 (2H,m), 2.1 (2H,t), 1.7 (2H,m) Compound X - Anal. Calcd for C23H29NO3: C, 75.16, H, 7.97, N, 3.79 Found:
C,74.90, H, 8.19, N, 3.38. 'H NMR (300MHz, CDCL3): 6 7.35 (2H,d), 7.27 (2H,d), 7.15 (2H,d), 6.95 (2H,d), 3.7 (1 H,q), 2.6 (2H,t), 2.5 (2H,d), 2.35 (2H,t), 1.9 (3H,m), 1.6 (3H,d), 0.9 (6H,d) Compound XVIII - 1H NMR (300MHz, DMSO-d6): 6 12.1 (1H,s), 10.5 (1H,s), 8.2 (1H,t), 8.0 (2H,m), 7.7 (3H,d), 7.6 (3H,d), 7.2 (2H,t), 3.3 (1H,m), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,t) Compound XXII - Anal. Calcd for CZOH23N03: C, 73.82, H, 7.12, N, 4.30 Found: C, 73.53, H, 7.07, N, 4.28. 'H NMR (300MHz, DMSO-d6): 6 12.0 (1 H,s), 10.0 (1 H,s), 7.6 (2H,m), 7.4 (4H,m), 7.2 (1H,d), 7.0 (2H,q), 3.55 (1H,t), 2.5 (4H,m), 2.2 (2H,q), 2.0 (1 H,m), 1.7 (3H,m), 0.9 (3H,t) Compound XXVI - 'H NMR (300MHz, D20): d' 7.21(2H, d), 7.15(2H, d), 2.51(2H,t), 2.45(1 H, m), 2.10(2H, t), 1.9-1.3(14H, m) Compound XXV - Anal. Calcd for C18H18N03F: C, 68.56, H, 5.75, N, 4.44 Found:
C, 68.18, H, 5.63, N, 4.20. 1H NMR (300 MHz, DMSO-d6): S 12.1 (1H,s), 10.1 (1H,s), 7.5 (2H,m), 7.35 (2H,m), 7.1 (4H,m), 3.6 (2H,s), 2.5 (2H,t), 2.2 (2H,t), 1.75 (2H,m) Compound XXVII - iH NMR (300MHz, DMSO-d6): S 9.75 (1H,s), 7.5 (2H,d), 7.1 (2H,d), 2.5 (3H,q), 2.05 (3H,t), 1.6 (10H,m), 1.1 (5H,m), 0.8 (3H,t) Compound XXVIII - 'H NMR (300MHz, DMSO-d6): S 9.82(1H, s), 7.49(2H, d), 7.06(2H,d), 2.48(2H, t), 2.32(1H, m), 2.09(2H, t), 1.71(8H, m), 1.29(6H, m) Compound XXIX - iH NMR (300MHz, DMSO-d6): S 10.0 (1H,s), 7.5 (2H,d), 7.05 (2H,d), 2.5 (3H,m), 2.15 (2H,d), 1.85 (2H,t), 1.65 (8H,m), 1.2 (3H,m), 1.90(2H,q) Compound XXX -'H NMR (300MHz, DMSO-db): 6 9.85 (1H,d), 7.5 (2H,d), 7.05 (2H,d), 2.45 (3H,m), 1.9 (2H,t), 1.7 (6H,m), 1.4 (4H,m), 0.9 (3H,dd) Compound XXXIII - 1H NMR (300MHz, DMSO-d6): 6 11.95(1H, s), 2.2(2H, m), 1.8(2H, m), 1.4(10, br m), 0.83(3H, d) Compound XXXIV - Anal. Calcd for C15H19NO3: C 68.96, H 7.26, N5.36, Found: C
68.75, H 7.24, N 5.30. 1H NMR (300MHz, D20): S 7.71(2H, d), 7.33(2H, d), 2.06(2H, d), 1.52(6H, m), 1.01(3H, m), 0.84(2H, m) Compound XXXV - Anal. Calcd for C14H1QN03C1: C, 60.96, H, 3.63, N, 5.08 Found:
C, 60.42, H, 3.64, N, 4.94. 'H NMR (300MHz, DMSO-db): S 10.85 (1H,s), 7.95 (2H,d), 7.85 (2H,d), 7.55 (4H,m) Compound XXXVI - Anal. Calcd for C16H21N03: C 69.79, H 7.70, N 5.08, Found:
C 69.38, H 7.85, N 4.85. 1H NMR (300MHz, DMSO-d6): S 10.0)1H, s), 7.45(2H, d), 7.10(2H, d), 3.18(2H, s), 2.15(2H, d), 1.67(6H, br m), 1.17(3H, m), 0.95(2H, m) Compound XXXVII - 'H NMR (300MHz, DMSO-d6): 6 12.25(1H, s), 9.8(1H,s), 7.5(2H, d), 7.15(2H, d), 3.5(2H, s), 2.3(1H, m), 1.8(4H, m), 0.3(6H, m) Compound XXXVIII - Anal. Calcd for C17H15N03: C, 72.58, H, 5.39, N, 4.98 Found:
C, 72.34, H, 5.21, N, 4.93. 'H NMR (300MHz, DMSO-d6): S 10.2 (1H,s), 7.6 (5H,m), 7.4 (3H,q), 7.2 (2H,d), 6.85 (1H,d), 3.5 (2H,s) Compound XL - 'H NMR (300MHz,DMSO-d6): S 8.6 (1H,m), 7.8 (2H,m), 7.25 (5H,m), 7.1 (2H,dd), 4.25 (2H,d), 3.5 (2H,s) Compound XLI - Anal. Calcd for C15H13N03. 0.27 H20: C, 70.57, H, 5.14, N, 5.49 Found: C, 69.24, H, 5.48, N, 5.37. 'H NMR (300MHz, DMSO-db): 6 10.25 (1H,s), 8.0 (2H,d), 7.7 (2H,d), 7.55 (3H,m), 7.25 (2H,d), 3.5 (2H,s) Compound XLII - 'H NMR (300MHz, DMSO-d6): S 11.89(1H, s), 7.58 (1H,s), 2.95(2H, t), 2.16(3H, m), 1.73(2H, t), 1.40(14H, m), 1.20(2H, t) Example 2 Compound IX was prepared as follows:
A solution of 4-phenylbutyryl chloride (10.20g, 56 mmol) in tetrahydrofuran (30 mL) was added dropwise to a mixture of 4-(4-aminophenyl)butyric acid (10.OOg, 56 mmol, 1.0 equiv.), triethylamine (8.50 mL, 62 mmol, 1.1 equiv.) and tetrahydrofuran (100 mL) at 10 C. The reaction was stirred at 10 C for 1 hour and 25 C for 3 hours. The solvent was then evaporated, and the residue was dissolved in ethyl acetate (150 mL). After washing the ethyl acetate layer with aqueous hydrochloric acid (1 M, 3 x 100 mL) and water (2 x 100 mL), the organic layer was dried and evaporated. The resultant residue was recrystallized from acetonitrile-water to give IX as a pale yellow solid (11.69g, 65 %).
Properties are listed below.
I H NMR (300MHz, alkaline D20) 6: 7.05 (2H, m), 6.94 (4H, m), 6.85 (3H, m), 2.30 (4H, m) 2.01 (4H, m), 1.61 (4H, m). Anal. Calcd for C20H23N03: C, 73.81; H, 7.13; N, 4.30. Found: C, 73.53; H, 7.13; N, 4.25.
Similar procedures were used to prepare compounds I. III, IV, VII, VIII, XVII, XX and XXI.
Properties are listed below.
Compound I - 'H NMR (300MHz,D20): 6 7.75 (2H,q), 7.55 (1H,m), 7.45 (2H,m), 7.35 (2H,dd), 7.2 (2H,dd), 2.55 (2H,m), 2.1 (2H,t), 1.75 (2H,m) Compound III - Anal. Calcd for CõH16N03C1: C, 64.26, H,5.07, N,4.41 Found:
C, 63.29, H, 5.12, N, 4.19. ' H NMR (300MHz, DMSO-ds): 6 12.1 (1 H,s), 10.4 (1 H,s), 7.7 (2H,d), 7.6 (2H,d), 7.45 (2H,m), 7.2 (2H,q), 2.6 (2H,m), 2.2 (2H,m), 1.8 (2H,m) Comaound IV - Anal. Calcd for CõH,BN03F: C, 67.76, H, 5.35, N, 4.65 Found:
C, 67.15, H, 5.33, N, 4.46. 'H NMR (300MHz, DMSO-ds): 6 12.05 (1 H,s), 10.35 (1 H,s), 7.6 (4H,m), 7.3 (2H,q), 7.15 (2H,q), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,m) ComQound VII -'H NMR (300MHz, D20): 6 7.12(3H, m), 6.88(2H, s), 6.67(5H, br m), 6.26(1 H, d), 2.18(2H, t), 1.96(2H, t), 1.50(2H, q) Compound VIII - 'H NMR (300MHz, D20): 6 6.9 (9H,m), 2.6 (2H,t), 2.3 (4H,t), 2.0 (2H,q), 1.6 (2H,m) Example 3 Compound XXIV was prepared as follows:
N-hydroxysuccinamide (8.86 g, 77.00 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (15.88 g, 77.00 mmol, 1.1 equiv.) were added to a solution of 3-(4-fluorobenzoyl)propionic acid (13.73 g, 70.00 mmol, 1 equiv.) in dimethylformamide (250 mL). The reaction was stirred at 26 C under nitrogen for 12 hours. The solution was diluted with water (500 mL) and extracted with chloroform (250 mL). The organic layer was dried and filtered.
Glacial acetic acid (5 mL) was added to the filtrate, and this mixture stirred for 1 hour. The resulting chloroform solution was washed with sodium bicarbonate (250 mL) and water (250 mL) and dried over magnesium sulfate. After filtration, 4-(4-aminophenyl)butyric acid (12.5 g, 70.00 mmol, 1 equiv.) and triethylamine (16 mL) were added to the filtrate. The resulting mixture was stirred at 25 C overnight, and it was then acidified with hydrochloric acid (250 mL) and lyophilized to yield XXIV as a white solid. (3.50 g, 14%).
Properties are listed below.
'H NMR (300MHz, DMSO-d6) d': 12.05 (H, br s), 9.95 (1 H, s), 8.10 (2H, t), 7.50 (2H, d), 7.35 (2H, t), 7.10 (1 H, d), 2.70 (2H, t), 2.20 (2H, t), 1.75 (2H, m). Anal. Calcd for C20HZON04F: C, 67.02; H, 5.62; N, 3.90. Found: C, 67.08; H, 5.60; N, 3.86.
Similar procedures were used to prepare compound XLIII and XLIV.
Properties are listed below.
Compound XLIII - Anal. Calcd for C22H27NO3' 0.083 H20: C, 74.44, H, 7.73, N, 3.95 Found: C, 73.96, H, 7.73, N, 4.26. 1H NMR (300MHs, DMSO-d6): 6 12.71 (1H,s), 8.2 (1H,q), 7.1 (9H,m), 4.4 (1H,m), 3.6 (1H,m), 3.0 (1H,m), 2.85 (1H,m), 2.4 (1H,q), 1.8 (1H,m), 1.3 (2H,d), 1.15 (1H,d), 0.85 (6H,d) Comgound XLIV - Anal. Calcd for C22H17NO4F2: C, 66.49, H, 4.32, N, 3.53 Found: C, 66.14, H, 4.29, N, 3.33. ' H NMR (300MHz, DMSO-d6): d 8.05 (1 H,s), 7.5(2H,m), 7.35 (1 H,m), 7.2(7H,m), 7.0 (1 H,d), 4.7 (1 H,m), 3.2 (1 H, dd), 3.05 (1 H, m) Example 4 Compound XXXII was prepared as follows:
1-oxaspiro(2.5)octane (3.76 g, 33.48 mmol, 1.2 equiv.) and aluminum chloride (0.36 g, 2.70 mmol, 0.1 equiv.) were added to a suspension of 4-(4-aminophenyl)butyric acid (5.00 g, 27.90 mmol, 1 equiv.) in toluene (100 mL) . The mixture was refluxed under argon overnight. After being cooled to room temperature, the toluene was filtered, and the residue was washed with ethyl acetate (ca. 100mL). The combined filtrate was evaporated to yield a brown gum. The gum was dissolved with ethyl acetate (250 mL). It was then washed with water (3 x 100mL) and dried. After removal of the solvent, the residue was purified by column chromatography (30 % to 70 % ethyl acetate/hexanes), and the collected product was recrystallized from ethyl acetate-hexanes to give XXXII as yellow solid (0.8 g, 10 Properties are listed below.
'H NMR (300 MHz, DMSO-de) 6: 6.85 (2H, d, J = 8.4 Hz), 6.53 (2H, d, J = 8.4 Hz), 5.00 (1 H, br s), 2.88 (2H, s), 2.39 (2H, t, J
= 7.2 Hz), 2.15 (2H, t, J= 7.4 Hz), 1.69 (2H, m), 1.45 (10H, m). Anal. Calcd for CõH25 NO3: C, 70.07; H, 8.65; N, 4.81.
Found: C, 70.20; H, 8.69; N, 4.67.
Examp(e 5 Compound XXXIX was prepared as follows:
N-hydroxysuccinimide (7.72 g, 67.50 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (13.96 g, 67.50 mmol, 1.1 equiv.) were added to a solution of N-(2-phenylbutyryl)-4-(aminophenyl)butyric acid (20.00 g, 61.40 mmol, 1.0 equiv.) in tetrahydrofuran (400 mL). The reaction was stirred overnight at 25 C. The urea formed was removed by filtration. Glacial acetic acid (5 mL) was added to the filtrate and stirred for 2 hours. The solvent was then evaporated to yield an oil. The oil was redissolved in chloroform (300 mL), and the resultant solution was washed successively with saturated sodium bicarbonate (2 x 200 mL) and water (200 mL). The combined aqueous layers were extracted with chloroform (100 mL) to give a filtrate (a total volume of 500 mL) containing the 0-succinyl ester of N-(2-phenylbutyryl)-4-(4-aminophenyl)butyric acid.
A mixture of pheriyiglycine 0-methylester hydrochloride (12.40 g, 61.40 mmol, 1.0 equiv.) and triethylamine (35 mL) in chloroform (100 mL) was charged to an addition funnel. The mixture was added dropwise to the chloroform solution of the Osu ester prepared above. The reaction was stirred at 25 C for 24 h. The resulting solution was washed with aqueous hydrochloric acid (2 x 500 mL) and water (500 mL). The aqueous layer was back extracted with chloroform (50 mL). The combined chloroform layers were dried and evaporated to yield an oil. Aqueous sodium hydroxide (2M, 200mL) was added to the oil, and the mixture was heated to 100 C for 2 h. After being cooled to room termerature, the solution was acidified with hydrochloric acid (2 M) to pH
2.5. The precipitate was filtered, washed with hydrochloric acid (100 mL) and water (100mL) to give XXXIX as an off white solid (15.2 g, 54%).
Properties are listed below.
' H NMR (300MHz, DMSO-dg) d: 12.70 (1 H, br s), 10.00 (1 H, s), 8.55 (1 H, d), 7.50 (2H, d), 7.33 (10H, m), 7.06 (2H, d), 5.32 (1 H, d), 3.54 (1 H, m), 2.49 (2H, overlapped with DMSO), 2.16 (2H, m), 2.05 (1 H, m), 1.73 (3H, m). 0.83 (3H, t). Anal. Calcd for C2$H30N204: C, 73.30; H, 6.61; N, 5.73; Found: C, 72.54; H, 6.60; N, 5.73.
Example 6-/n Vivo Evaluation of Interferon in Rats Dosing compositions were prepared by mixing the modified amino acid compounds and interferon a2 as listed in Table 1 below in a Trizma hydrochloride buffer solution (Tris-Hcl) at a pH of about 7-8. Propylene glycol (0-25%) was added as a solubilizing agent, if necessary.
Rats were orally or intraduodenaGiy (ID) administered the dosing compositions, and delivery was evaluated by an ELISA assay for human interferon a-2b.
Results are illustrated in Table 1 below.
Oral Delivery of Interferon Carrier Carrier Dose Interferon Dose Mean Peak Serum Levels (mg/kg) (/ag/kg) of Interferon (ng/mL) XXVI 300 1000 6710 +/- 6658 5 XXXVII 160 1000 1025 +/- 276 XXVII 300 1000 3642 +/- 5895 XXXIV 400 1000 11341 +/- 8793 400 500 565 +/-515 XXXIV (ID) 400 100 1775 +/- 1023 10 XXIX 600 100 3510 +/- 2171 I 300 1000 10072 +/-3790 I(ID) 250 50 843 +/- 669 I 80 250 1369 +/-1164 VI 300 1000 8213 +/- 3077 15 VI 600 1000 8428 +/- 5001 VI (ID) 1000 15469 +/- 6712 XXXVI 400 1000 43961 +/- 14910 XIV 800 1000 5518 +/- 2718 VI I 600 1000 5568 +/- 3771 20 XXVII 300 1000 41966 +/- 19688 VIII 300 1000 1753 +/- 1529 XVIII 300 1000 19809 +/- 26107 XXX 300 1000 3910 +/- 3221 XL 300 1000 12661 +/-10933 25 none 0 1000 688 +/-173 Example 7-/n Vivo Evaluation of Salmon Calcitonin in Rats Dosing compositions were prepared and dosed using the modified amino acid compound carriers and salmon calcintonin as listed in Table 2 below.
30 The concentration of calcitonin in each composition was 2.5 Ng/ml. Each rat was administered 2 mi/kg of dosing composition.
Blood samples were collected serially from the tail artery. Serum calcium was determined by testing with a Calcium Keto (Sigma Chemical Co. -St. Louis, MO.) Results are illustrated in Table 2 below.
Example 8 - In Vivo Evaluation of Salmon Concentration in Rats A dosing composition was prepared using 400 mg of compound VI
with 2.9 ml of 25% aqueous propylene glycol. The resultant solution was stirred, and the pH was adjusted to 7.2 with sodium hydrochloride (1.01N).
Water was added to bring the total volume to 2.0 ml and a final modified amino acid concentration of 200 mg/mi. Salmon calcitonin (10 mg) was added.
This composition was dosed as described in Example 7 above.
Results are illustrated in Table 2 below.
Oral Delivery of Calcitonin Carrier Carrier Dose Dose Drug Mean Peak Serum Levels (mg/kg) (pg/kg) of calcitonin(ng/mL) XXVI 10 300 -18 +/- 6 XXVIII 10 200 -14 +/- 6 1 10 200 -16 + /- 8 VII 10 200 -13 +/- 8 VI 10 200 -29 + /- 14 10 -13 +/- 4 10 30 -24 + /- 9 Example 9 In Vivo Evaluation of Recombinant Human Growth Hormone (rhGh) in Rats Dosing compositions were prepared with modified amino acids in a phosphate buffer at a pH of about 7-8 and rhGH as listed in Table 3 below.
Rats were administered the compositions by oral gavage, intraduodenal administration (ID), or colonic administration (IC).
Results are illustrated in Table 3 below.
Oral Delivery of rhGH
Carrier Carrier Dose Dose Drug Mean Peak Serum Levels (mg/mL) (mg/mL) of rhGH (ng/mL) XXVI 500 6 -127 +/- 40 XXVII 500 6 -64 +/- 7 VI 150 6 -33 +/- 13 VI (ID) 200 3 -103 +/-85 VI (IC) 50 1.5 -98 +/- 19 II 400 6 55 +/-36 XXX 400 6 66 +/-37 XLV 400 6 28 +/- 9 IV 300 6 42 +/- 29 XLI I I 300 6 63 +/- 45 X 250 6 37 +/- 12 XXXI I 200 6 44 +/- 36 none 0 6- 1 <10 Example 10 -/n Vivo Evaluation of Heparin in Rats 900 mg of modified amino acid were dissolved in 3 mi of propylene glycol, and 0.299 gram of sodium heparin was dissolved in 3 ml of water. The two solutions were mixed by vortex. Sodium hydrochloride was added to the resultant mixture until a solution was obtained. The pH was then adjusted to 7.4 0.5 with concentrated hydrochloric acid. The final solution was sonicated at 40 C for 30 minutes to yield a dosing solution.
The dosing solution was administered by oral gavage to fasted rats.
Blood samples were collected by cardiac puncture following the administration of ketamine (44 mg/kg). Heparin activity was determined by utilizing the activated partial thromboplastin time (APTT) according to the method of Henry, J. B., Clinical Diagnosis and Management by Laboratory Methods; Philadelphia, PA; WB Saunders (1979). Results are illustrated in Table 4 below.
Oral Delivery of Heparin IF Carrier Mean Peak APTT (sec) # Animals Responding XXI 166 + /- 35 5/5 IX 102 +/- 33 34/35 VI 96 +/- 29 10/10 XLI 90 + 1- 49 5/5 XXXV 73 + /- 16 4/4 VI I 52 +/-24 17/20 E-466 67 + /- 30 4/5 XX 59 +/-42 4/4 VII 58 +/-28 14/15 XLII 45 + /- 14 5/5 XXXIII 44 +/- 28 12/20 XXVI I 44 +/- 15 18/20 V 42 +/-16 4/5 111 41 +/- 18 8/10 II 41 +/-24 3/5 XXXIX 40 +/- 17 5/10 XIX 37 +/- 11 4/5 XXII 36 +/- 19 6/11 XXVIII 35 +/- 9 3/5 none 20.7 +/- 0.17 100/100 Example 11 Low molecular weight heparin was dosed according to the method of Example 10.
Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. AII
such obvious variations are within the full intended scope of the appended claims.
NY
OH
N XLII
H O
\ O /
OH
H XLIII
O
HO O
OH
F
W
\ I XLIV
O ~ I H XLV
H \ O
or salts thereof.
Compositions comprising at least one biologically active agent and at least one of the compounds above are also provided. Further contemplated by the present invention are dosage unit forms that include these compositions.
Also contemplated is a method for preparing these compositions which comprises mixing at least one active agent with at least one compound as described above, and optionally, a dosing vehicle.
In an alternative embodiment, these non-toxic compounds are orally administered to animals as part of a delivery system by blending or mixing the compounds with an active agent prior to administration.
DETAILED DESCRIPTION OF THE INVENTION
The specific compounds of the present invention or salts thereof such as, for example, sodium salts, may be used to deliver various active agents through various biological, chemical, and physical barriers. These compounds are particularly suited for delivering active agents which are subject to environmental degradation. The compounds and compositions of the subject invention are particularly useful for delivering or administering biologically-active agents to any animals such as birds; mammals, such as primates and particularly humans; and insects.
Other advantages of the present invention include the use of easy to prepare, inexpensive raw materials. The compositions and the formulation methods of the present invention are cost effective, simple to perform, and amenable to industrial scale up for commercial production.
Amino acids, poly amino acids, and peptides, in modified form, may be used to deliver active agents including, but not limited to, biologically active agents such as for example, pharmacological and therapeutic agents.
An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids.
Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g. an ester, anhydride, or an anhydride linkage. Special mention is made of non-naturally occurring poly amino acids and particularly non-naturally occurring hetero poly amino acids, i.e. polymers of mixed amino acids.
Peptides are two or more amino acids joined by a peptide bond.
Peptides can vary in length from dipeptides with two amino acids to poly peptides with several hundred amino acids. See Chambers Biological Dictionary, editor Peter M. B. Walker, Cambridge, England: Chambers Cambridge, 1989, page 215. Special mention is made of di-peptides, tri-peptides, tetra-peptides, and penta-peptides.
The terms modified amino acids, modified poly amino acids, and modified peptides are meant to include amino acids which have been modified or poly amino acids and peptides in which at least one amino acid has been modified by acylating at least one free amine group with an acylating agent which reacts with at least one of the free amine groups present.
Modified Amino Acids Several of the compounds of the present invention are broadly represented by one of formula XLVI or XLVII below:
Ar-Y-(R')n-OH XLVI
wherein Ar is a substituted or unsubstituted phenyl or naphthyl;
(1 11 Y is - C- or -SO2-, R' has the formula -N(R3)-R2-C-, wherein:
RZ is C, to C24 alkyl, C, to C24 alkenyl, phenyl, naphthyl, (C, to Clo alkyl) phenyl, (C, to C,o alkenyl) phenyl, (C, to C,o alkyl) naphthyl, (C, to Clo alkenyl) naphthyl, phenyl (Cl to C,o alkyl), phenyl (C, to C,o alkenyl), naphthyl (C, to C,o alkyl), and naphthyl (C, to C,o alkenyl);
R2 is optionally substituted with C, to C4 alkyl, C, to C4 alkenyl, C, to C4 alkoxy, -OH, -SH and -C02R4 or any combination thereof;
R4 is hydrogen, C, to C4 alkyl or C, to C4 alkenyl;
R2 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and R3 is hydrogen, C, to C4 alkyl or C, to C4 alkenyl; or RS-OH XLVII
wherein: R5 is (i) C3-C,p cycloalkyl, optionally substituted with C,-C7 alkyl, C2-C7 alkenyl, C1-C7 alkoxy, hydroxy, phenyl, phenoxy or -C02R8, wherein R8 is hydrogen, C1-C4 alkyl, or C2-C4 alkenyl; or (ii) C,-C6 alkyl substituted with C3 C,o cycloalkyl;
R6 is hydrogen, C,-C4 alkyl, or C2-C4 alkenyl;
R' is C1-C24 alkyl, C2-C24 alkenyl, C3 C,o cycloalkyl, C3 C,o cycloalkenyl, phenyl, naphthyl, (C,-C,o alkyl) phenyl, (C2-C,o alkenyl) phenyl, (C,-C,o alkyl) naphthyl, (CZ C,o alkenyl) naphthyl, phenyl (C,-C,o alkyl), phenyl (C2 C,o alkenyl), naphthyl (C,-C,o alkyl) or naphthyl (CZ C,o alkenyl);
R' being optionally substituted with C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, -OH, -SH, -C02R9, C3-C,o cycloalkyl, C3 C,o cycloalkenyl, heterocycle having 3-10 ring atoms wherein the hetero atom is one or more of N, 0, S or any combination thereof, aryl, (C,-C,o alk)aryl, ar(C,-C,o alkyl), or any combination thereof;
R' being optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof; and R9 is hydrogen, C1-C4 alkyl, or C; C4 alkenyl.
Special mention is made of compounds I - XLV above.
The modified amino acids of formulae I-XLV may be prepared by reacting single amino acids, mixtures of two or more amino acids, amino acid esters, or amino acid amides, with an amine modifying agent which reacts with free amino moieties present in the amino acids to form amides.
Modified amino acids are typically prepared by modifying the amino acids or an ester thereof. Many of these compounds are prepared by acylation with acylating agents having the formula wherein: R10 is the appropriate radical to yield the modification indicated in the final product as would be within the skill of the art based upon the detailed disclosure herein, and Y is a leaving group. Typical leaving groups include, but are not limited to, halogens such as, for example, chlorine, bromine, and iodine.
Additionally, the corresponding anhydrides are suitable acylating agents.
Many of the compounds of the present invention can be readily prepared and modified by methods within the skill of those in the art based upon the present disclosure. For example, the modified amino acid compounds above may be prepared by reacting the single amino acid with the appropriate acylating agent or an amine modifying agent which reacts with free amino moiety present in the amino acids to form amides. Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art.
For example, the amino acid can be dissolved in aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide, and heated at a temperature ranging between about 5 C and about 70 C, preferably between about 10 C and about 40 C, for a period ranging between about 1 hour and about 4 hours, preferably about 2.5 hours. The amount of alkali employed per equivalent of NH2 groups in the amino acid generally ranges between about 1.25 and about 3 mmole, preferably between about 1.5 and about 2.25 mmole per equivalent of NH2. The pH of the solution generally ranges between about 8 and about 13, preferably ranging between about 10 and about 12.
Thereafter, the appropriate amino modifying agent is added to the amino acid solution while stirring. The temperature of the mixture is maintained at a temperature generally ranging between about 5 C and about 70 C, preferably between about 10 C and about 40 C, for a period ranging between about 1 and about 4 hours. The amount of amino modifying agent employed in relation to the quantity of amino acid is based on the moles of total free NH2 in the amino acid. In general, the amino modifying agent is employed in an amount ranging between about 0.5 and about 2.5 mole equivalents, preferably between about 0.75 and about 1.25 equivalents, per molar equivalent of total NH2 group in the amino acid.
The reaction is quenched by adjusting the pH of the mixture with 5 a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between about 2 and about 3. The mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate. The upper layer is discarded, and the modified amino acid is collected from the lower layer by filtration or decantation. The crude modified 10 amino acid is then dissolved in water at a pH ranging between about 9 and about 13, preferably between about 11 and about 13. Insoluble materials are removed by filtration and the filtrate is dried in vacuo. The yield of modified amino acid generally ranges between about 30 and about 60%, and usually about 45%.
15 If desired, amino acid esters, such as, for example methyl or ethyl esters of amino acid compounds, may be used to prepare the modified amino acids of the invention. The amino acid ester, dissolved in a suitable organic solvent such as dimethylformamide or pyridine, is reacted with the appropriate amino modifying agent at a temperature ranging between about 5 C and about 700C, preferably about 250C, for a period ranging between about 7 and about 24 hours. The amount of amino modifying agent used relative to the amino acid ester is the same as described above for amino acids.
Thereafter, the reaction solvent is removed under negative pressure and the ester functionality is removed by hydrolyzing the modified amino acid ester with a suitable alkaline solution, e.g. 1 N sodium hydroxide, at a temperature ranging between about 50 C and about 80 C, preferably about 70 C, for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group. The hydrolysis mixture is then cooled to room temperature and acidified, e.g. aqueous 25%
hydrochloric acid solution, to a pH ranging between about 2 and about 2.5. The modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.
The modified amino acid may be purified by recrystallization or by fractionation on solid column supports. Suitable recrystallization solvent systems include acetonitrile, methanol and tetrahydrofuran. Fractionation may be performed on a suitable solid column supports such as alumina, using methanol/n-propanol mixtures as the mobile phase; reverse phase column supports using trifluoroacetic acid/acetonitrile mixtures as the mobile phase;
and ion exchange chromatography using water as the mobile phase. When anion exchange chromatography is performed, preferably a subsequent 0-500 mM
sodium chloride gradient is employed.
Active Agents Active agents suitable for use in the present invention include biologically active agents, chemically active agents, including, but not limited to, fragrances, as well as other active agents such as, for example, cosmetics.
Biologically active agents include, but are not limited to, pesticides, pharmacological agents, and therapeutic agents. For example, biologically active agents suitable for use in the present invention include, but are not limited to, peptides, and particularly small peptides; hormones, and particularly hormones which by themselves do not or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; or any combination thereof. Further examples include, but are not limited to, human growth hormones; bovine growth hormones; growth releasing hormones; interferons; interleukin-n~
insulin;
heparin, and particularly low molecular weight heparin; calcitonin;
erythropoietin;
atrial naturetic factor; antigens; monoclonal antibodies; somatostatin;
adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin;
cromolyn sodium (sodium or disodium chromoglycate); vancomycin;
desferrioxamine (DFO); anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.
Delivery Systems The compositions of the present invention may include one or more active agents.
In one embodiment, compounds I-XLV or poly amino acids or peptides that include at least one of these compounds may be used directly as a drug delivery carrier by simply mixing one or more compound, poly amino acid or peptide with the active ingredient prior to administration.
In an alternative embodiment, the compounds, poly amino acids, or peptide may be used to form microspheres containing the active agent.
These compounds, poly amino acids, or peptides are particularly useful for the oral administration of certain biologically-active agents, e.g., small peptide hormones, which, by themselves, do not pass or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastrointestinal tract.
If the modified amino acids, poly amino acids, or peptides are to be converted into microspheres, the mixture is optionally heated to a temperature ranging between about 20 and about 50 C, preferably about 40 C, until the modified amino acid(s) dissolve. The final solution contains between from about 1 mg and to about 2000 mg of compound, poly amino acid, or peptide per mL
of solution, preferably between about 1 and about 500 mg per mL. The concentration of active agent in the final solution varies and is dependent on the required dosage for treatment. When necessary, the exact concentration can be determined by, for example, reverse phase HPLC analysis.
When the compounds, poly amino acids, or peptides are used to prepare microspheres, another useful procedure is as follows: Compounds, poly amino acids, or peptides are dissolved in deionized water at a concentration ranging between about 75 and about 200 mg/ml, preferably about 100 mg/ml at a temperature between about 25 C and about 60 C, preferably about 40 C.
Particulate matter remaining in the solution may be removed by conventional means such as filtration.
Thereafter, the compound, poly amino acid, or peptide solution, maintained at a temperature of about 40 C, is mixed 1:1 (V/V) with an aqueous acid solution (also at about 40 C) having an acid concentration ranging between about 0.05 N and about 2 N, preferably about 1.7 N. The resulting mixture is further incubated at 40 C for a period of time effective for microsphere formation, as observed by light microscopy. In practicing this invention, the preferred order of addition is to add the compound, poly amino acid, or peptide solution to the aqueous acid solution.
Suitable acids for microsphere formation include any acid which does not (a) adversely effect the modified amino acids, poly amino acids, or peptides e.g., initiate or propagate chemical decomposition;
(b) interfere with microsphere formation;
(c) interfere with microsphere incorporation of the cargo;
and (d) adversely interact with the cargo.
Preferred acids for use in this aspect include acetic acid, citric acid, hydrochloric acid, phosphoric acid, malic acid and maleic acid.
A microsphere stabilizing additive may be incorporated into the aqueous acid solution or into the compound or cargo solution prior to the microsphere formation process. With some drugs the presence of such additives promotes the stability and/or dispersibility of the microspheres in solution.
The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (w/v), preferably about 0.5 % (w/v).
Suitable, but non-limiting, examples of microsphere stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine.
The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
Under the above conditions, the compound molecules, poly amino acids, or peptides form hollow or solid matrix type microspheres wherein the cargo is distributed in a carrier matrix or capsule type microspheres encapsulating liquid or solid cargo. If the compound, poly amino acid, or peptide microspheres are formed in the presence of a soluble material, e.g., a pharmaceutical agent in the aforementioned aqueous acid solution, this material will be encapsulated within the microspheres. In this way, one can encapsulate pharmacologically active materials such as peptides, proteins, and polysaccharides as well as charged organic molecules, e.g., antimicrobial agents, which normally have poor bioavailability by the oral route. The amount of pharmaceutical agent which may be incorporated by the microsphere is dependent on a number of factors which include the concentration of agent in the solution, as well as the affinity of the cargo for the carrier. The compound, poly amino acid, or peptide microspheres do not alter the physiological and biological properties of the active agent. Furthermore, the encapsulation process does not alter the pharmacological properties of the active agent. Any pharmacological agent can be incorporated within the microspheres. The system is particularly advantageous for delivering chemical or biological agents which otherwise would be destroyed or rendered less effective by conditions encountered within the body of the animal to which it is administered, before the microsphere reaches its target zone (i. e., the area in which the contents of the microsphere are to be released) and for delivering pharmacological agents which are poorly absorbed in the gastro-intestinal tract. The target zones can vary depending upon the drug employed.
The particle size of the microsphere plays an important role in determining release of the active agent in the targeted area of the gastro-intestinal tract. The preferred microspheres have diameters between about <
0.1 microns and about 10 microns, preferably between about 0.5 microns and about 5 microns. The microspheres are sufficiently small to release effectively the active agent at the targeted area within the gastro-intestinal tract such as, for example, between the stomach and the jejunum. Small microspheres can also be administered parenterally by being suspended in an appropriate carrier fluid (e.g., isotonic saline) and injected directly into the circulatory system, intramuscularly or subcutaneously. The mode of administration selected will vary, of course, depending upon the requirement of the active agent being administered. Large amino acid microspheres (>50 microns) tend to be less effective as oral delivery systems.
The size of the microspheres formed by contacting compounds, poly amino acids, or peptides with water or an aqueous solution containing active agents can be controlled by manipulating a variety of physical or chemical parameters, such as the pH, osmolarity or ionic strength of the encapsulating solution, size of the ions in solution and by the choice of acid used in the encapsulating process.
The administration mixtures are prepared by mixing an aqueous solution of the carrier with an aqueous solution of the active ingredient, just prior to administration. Alternatively, the carrier and the biologically active ingredient can be admixed during the manufacturing process. The solutions may 5 optionally contain additives such as phosphate buffer salts, citric acid, acetic acid, gelatin and gum acacia.
. Stabilizing additives may be incorporated into the carrier solution.
With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution.
10 The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5 % (W/V), preferably about 0.5 % (W/V).
Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
15 The amount of active agent is an amount effective to accomplish the purpose of the particular active agent. The amount in the composition typically is a pharmacologically or biologically effective amount. However, the amount can be less than a pharmacologically or biologically effective amount when the composition is used in a dosage unit form, such as a capsule, a tablet 20 or a liquid, because the dosage unit form may contain a multiplicity of carrier/biologically active agent compositions or may contain a divided pharmacologically or biologically effective amount. The total effective amounts can then be administered in cumulative units containing, in total, pharmacologically or biologically active amounts of biologically or pharmacologically active agent.
The total amount of active agent, and particularly biologically active agent, to be used can be determined by those skilled in the art. However, it has surprisingly been found that with some biologically active agents, the use of the presently disclosed carriers provides extremely efficient delivery. Therefore, lower amounts of biologically active agent than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and therapeutic effects.
The amount of carrier in the present composition is a delivery effective amount and can be determined for any particular carrier or biologically active agent by methods known to those skilled in the art.
Dosage unit forms can also include any of excipients; diluents;
disintegrants; lubricants; plasticizers; colorants; and dosing vehicles, including, but not limited to water, 1,2-propane diol, ethanol, olive oil, or any combination thereof.
Administration of the present compositions or dosage unit forms preferably is oral o.r by intraduodenal injection.
The delivery compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof.
These compounds have the formulas below:
Me-,Me Y O
NHOH
~
HO/ O H O
XLIX
Me Actinonin Me' Me Y O
NHOH
O H k 0 HO
Me L
Epiactnonin Derivatives of these compounds are disclosed in U.S. Patent No. 5,206,384.
Actinonin derivatives have the formula:
O
I I
R~r-C
~CH2 H 0 LI
N
O CH
CH3 \CH3 R71 wherein R12 is sulfoxymethyl or carboxyl or a substituted carboxy group selected from carboxamide, hydroxyaminocarbonyl and alkoxycarbonyl groups; and R13 is hydroxyl, alkoxy, hydroxyamino or sulfoxyamino group. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.
The compounds and compositions of the subject invention are useful for administering biologically active agents to any animals such as birds;
mammals, such as primates and particularly humans; and insects. The system is particularly advantageous for delivering chemically or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the active agent its target zone (i.e. the area in which the active agent of the delivery composition are to be released) and within the body of the animal to which they are administered. Particularly, the compounds and compositions of the present invention are useful in orally administering active agents, especially those which are not ordinarily orally deliverable.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples illustrate the invention without limitation.
Example 1 Compound VI was prepared as follows:
Acetylsalicyloyl chloride (47.00 g, 0.24 mol, 1 equiv.) was added portionwise to a mixture of 4-(4-aminophenyl)butyric acid (50.OOg, 0.28 mol, 1.2 equiv.) in aqueous sodium hydroxide (2M, 300 mL). The reaction was stirred at 25 C for 2 hours, and the resultant solution was acidified with aqueous hydrochloric acid (1 M) to pH 2.1. The resultant precipitate was filtered, and was washed with aqueous hydrochloric acid (1 M, 3 x 100 mL) and water to give Compound VI as a pale pink solid (31.89 g, 52%).
Properties are listed below.
'H NMR (300 MHz, DMSO-ds) 6: 7.74 (1H, dd), 7.38 (2H, d), 7.21 (3H, m), 6.67 (1 H, m), 6.57 (1 H, m), 2.48 (2H, t), 2.07 (2H, t), 1.71 (2H, m). Anal. Calcd for C17H17NO4: C, 68.20; H, 5.73;
N, 4.70. Found: C, 68.22; H, 5.61; N, 4.66.
Similar procedures were used to prepare Compounds II, V, X, XIV, XVIII, XXII, XXV, XXVI, XXVIi, XXVIII, XXIX, XXX, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XL, XLI, XLII, and XLV.
Properties are listed below.' Compound II -'H NMR (300MHz, D20): 6 7.23(9H, m), 3.62(2H, s), 2.50(2H, t), 2.17(2H, t), 1.73(2H, q) Compound V - Anal. Calcd for C17H17NO5: C, 64.74, H, 5.45, N, 4.44 Found:
C, 64.11, H, 5.46, N, 4.21. 'H NMR (300MHz, D20): 6 7.6 (1H,d), 7.35 (2H,d), 7.15 (2H,m), 6.05 (1 H,d), 2.5 (2H,m), 2.1 (2H,t), 1.7 (2H,m) Compound X - Anal. Calcd for C23H29NO3: C, 75.16, H, 7.97, N, 3.79 Found:
C,74.90, H, 8.19, N, 3.38. 'H NMR (300MHz, CDCL3): 6 7.35 (2H,d), 7.27 (2H,d), 7.15 (2H,d), 6.95 (2H,d), 3.7 (1 H,q), 2.6 (2H,t), 2.5 (2H,d), 2.35 (2H,t), 1.9 (3H,m), 1.6 (3H,d), 0.9 (6H,d) Compound XVIII - 1H NMR (300MHz, DMSO-d6): 6 12.1 (1H,s), 10.5 (1H,s), 8.2 (1H,t), 8.0 (2H,m), 7.7 (3H,d), 7.6 (3H,d), 7.2 (2H,t), 3.3 (1H,m), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,t) Compound XXII - Anal. Calcd for CZOH23N03: C, 73.82, H, 7.12, N, 4.30 Found: C, 73.53, H, 7.07, N, 4.28. 'H NMR (300MHz, DMSO-d6): 6 12.0 (1 H,s), 10.0 (1 H,s), 7.6 (2H,m), 7.4 (4H,m), 7.2 (1H,d), 7.0 (2H,q), 3.55 (1H,t), 2.5 (4H,m), 2.2 (2H,q), 2.0 (1 H,m), 1.7 (3H,m), 0.9 (3H,t) Compound XXVI - 'H NMR (300MHz, D20): d' 7.21(2H, d), 7.15(2H, d), 2.51(2H,t), 2.45(1 H, m), 2.10(2H, t), 1.9-1.3(14H, m) Compound XXV - Anal. Calcd for C18H18N03F: C, 68.56, H, 5.75, N, 4.44 Found:
C, 68.18, H, 5.63, N, 4.20. 1H NMR (300 MHz, DMSO-d6): S 12.1 (1H,s), 10.1 (1H,s), 7.5 (2H,m), 7.35 (2H,m), 7.1 (4H,m), 3.6 (2H,s), 2.5 (2H,t), 2.2 (2H,t), 1.75 (2H,m) Compound XXVII - iH NMR (300MHz, DMSO-d6): S 9.75 (1H,s), 7.5 (2H,d), 7.1 (2H,d), 2.5 (3H,q), 2.05 (3H,t), 1.6 (10H,m), 1.1 (5H,m), 0.8 (3H,t) Compound XXVIII - 'H NMR (300MHz, DMSO-d6): S 9.82(1H, s), 7.49(2H, d), 7.06(2H,d), 2.48(2H, t), 2.32(1H, m), 2.09(2H, t), 1.71(8H, m), 1.29(6H, m) Compound XXIX - iH NMR (300MHz, DMSO-d6): S 10.0 (1H,s), 7.5 (2H,d), 7.05 (2H,d), 2.5 (3H,m), 2.15 (2H,d), 1.85 (2H,t), 1.65 (8H,m), 1.2 (3H,m), 1.90(2H,q) Compound XXX -'H NMR (300MHz, DMSO-db): 6 9.85 (1H,d), 7.5 (2H,d), 7.05 (2H,d), 2.45 (3H,m), 1.9 (2H,t), 1.7 (6H,m), 1.4 (4H,m), 0.9 (3H,dd) Compound XXXIII - 1H NMR (300MHz, DMSO-d6): 6 11.95(1H, s), 2.2(2H, m), 1.8(2H, m), 1.4(10, br m), 0.83(3H, d) Compound XXXIV - Anal. Calcd for C15H19NO3: C 68.96, H 7.26, N5.36, Found: C
68.75, H 7.24, N 5.30. 1H NMR (300MHz, D20): S 7.71(2H, d), 7.33(2H, d), 2.06(2H, d), 1.52(6H, m), 1.01(3H, m), 0.84(2H, m) Compound XXXV - Anal. Calcd for C14H1QN03C1: C, 60.96, H, 3.63, N, 5.08 Found:
C, 60.42, H, 3.64, N, 4.94. 'H NMR (300MHz, DMSO-db): S 10.85 (1H,s), 7.95 (2H,d), 7.85 (2H,d), 7.55 (4H,m) Compound XXXVI - Anal. Calcd for C16H21N03: C 69.79, H 7.70, N 5.08, Found:
C 69.38, H 7.85, N 4.85. 1H NMR (300MHz, DMSO-d6): S 10.0)1H, s), 7.45(2H, d), 7.10(2H, d), 3.18(2H, s), 2.15(2H, d), 1.67(6H, br m), 1.17(3H, m), 0.95(2H, m) Compound XXXVII - 'H NMR (300MHz, DMSO-d6): 6 12.25(1H, s), 9.8(1H,s), 7.5(2H, d), 7.15(2H, d), 3.5(2H, s), 2.3(1H, m), 1.8(4H, m), 0.3(6H, m) Compound XXXVIII - Anal. Calcd for C17H15N03: C, 72.58, H, 5.39, N, 4.98 Found:
C, 72.34, H, 5.21, N, 4.93. 'H NMR (300MHz, DMSO-d6): S 10.2 (1H,s), 7.6 (5H,m), 7.4 (3H,q), 7.2 (2H,d), 6.85 (1H,d), 3.5 (2H,s) Compound XL - 'H NMR (300MHz,DMSO-d6): S 8.6 (1H,m), 7.8 (2H,m), 7.25 (5H,m), 7.1 (2H,dd), 4.25 (2H,d), 3.5 (2H,s) Compound XLI - Anal. Calcd for C15H13N03. 0.27 H20: C, 70.57, H, 5.14, N, 5.49 Found: C, 69.24, H, 5.48, N, 5.37. 'H NMR (300MHz, DMSO-db): 6 10.25 (1H,s), 8.0 (2H,d), 7.7 (2H,d), 7.55 (3H,m), 7.25 (2H,d), 3.5 (2H,s) Compound XLII - 'H NMR (300MHz, DMSO-d6): S 11.89(1H, s), 7.58 (1H,s), 2.95(2H, t), 2.16(3H, m), 1.73(2H, t), 1.40(14H, m), 1.20(2H, t) Example 2 Compound IX was prepared as follows:
A solution of 4-phenylbutyryl chloride (10.20g, 56 mmol) in tetrahydrofuran (30 mL) was added dropwise to a mixture of 4-(4-aminophenyl)butyric acid (10.OOg, 56 mmol, 1.0 equiv.), triethylamine (8.50 mL, 62 mmol, 1.1 equiv.) and tetrahydrofuran (100 mL) at 10 C. The reaction was stirred at 10 C for 1 hour and 25 C for 3 hours. The solvent was then evaporated, and the residue was dissolved in ethyl acetate (150 mL). After washing the ethyl acetate layer with aqueous hydrochloric acid (1 M, 3 x 100 mL) and water (2 x 100 mL), the organic layer was dried and evaporated. The resultant residue was recrystallized from acetonitrile-water to give IX as a pale yellow solid (11.69g, 65 %).
Properties are listed below.
I H NMR (300MHz, alkaline D20) 6: 7.05 (2H, m), 6.94 (4H, m), 6.85 (3H, m), 2.30 (4H, m) 2.01 (4H, m), 1.61 (4H, m). Anal. Calcd for C20H23N03: C, 73.81; H, 7.13; N, 4.30. Found: C, 73.53; H, 7.13; N, 4.25.
Similar procedures were used to prepare compounds I. III, IV, VII, VIII, XVII, XX and XXI.
Properties are listed below.
Compound I - 'H NMR (300MHz,D20): 6 7.75 (2H,q), 7.55 (1H,m), 7.45 (2H,m), 7.35 (2H,dd), 7.2 (2H,dd), 2.55 (2H,m), 2.1 (2H,t), 1.75 (2H,m) Compound III - Anal. Calcd for CõH16N03C1: C, 64.26, H,5.07, N,4.41 Found:
C, 63.29, H, 5.12, N, 4.19. ' H NMR (300MHz, DMSO-ds): 6 12.1 (1 H,s), 10.4 (1 H,s), 7.7 (2H,d), 7.6 (2H,d), 7.45 (2H,m), 7.2 (2H,q), 2.6 (2H,m), 2.2 (2H,m), 1.8 (2H,m) Comaound IV - Anal. Calcd for CõH,BN03F: C, 67.76, H, 5.35, N, 4.65 Found:
C, 67.15, H, 5.33, N, 4.46. 'H NMR (300MHz, DMSO-ds): 6 12.05 (1 H,s), 10.35 (1 H,s), 7.6 (4H,m), 7.3 (2H,q), 7.15 (2H,q), 2.6 (2H,t), 2.2 (2H,t), 1.8 (2H,m) ComQound VII -'H NMR (300MHz, D20): 6 7.12(3H, m), 6.88(2H, s), 6.67(5H, br m), 6.26(1 H, d), 2.18(2H, t), 1.96(2H, t), 1.50(2H, q) Compound VIII - 'H NMR (300MHz, D20): 6 6.9 (9H,m), 2.6 (2H,t), 2.3 (4H,t), 2.0 (2H,q), 1.6 (2H,m) Example 3 Compound XXIV was prepared as follows:
N-hydroxysuccinamide (8.86 g, 77.00 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (15.88 g, 77.00 mmol, 1.1 equiv.) were added to a solution of 3-(4-fluorobenzoyl)propionic acid (13.73 g, 70.00 mmol, 1 equiv.) in dimethylformamide (250 mL). The reaction was stirred at 26 C under nitrogen for 12 hours. The solution was diluted with water (500 mL) and extracted with chloroform (250 mL). The organic layer was dried and filtered.
Glacial acetic acid (5 mL) was added to the filtrate, and this mixture stirred for 1 hour. The resulting chloroform solution was washed with sodium bicarbonate (250 mL) and water (250 mL) and dried over magnesium sulfate. After filtration, 4-(4-aminophenyl)butyric acid (12.5 g, 70.00 mmol, 1 equiv.) and triethylamine (16 mL) were added to the filtrate. The resulting mixture was stirred at 25 C overnight, and it was then acidified with hydrochloric acid (250 mL) and lyophilized to yield XXIV as a white solid. (3.50 g, 14%).
Properties are listed below.
'H NMR (300MHz, DMSO-d6) d': 12.05 (H, br s), 9.95 (1 H, s), 8.10 (2H, t), 7.50 (2H, d), 7.35 (2H, t), 7.10 (1 H, d), 2.70 (2H, t), 2.20 (2H, t), 1.75 (2H, m). Anal. Calcd for C20HZON04F: C, 67.02; H, 5.62; N, 3.90. Found: C, 67.08; H, 5.60; N, 3.86.
Similar procedures were used to prepare compound XLIII and XLIV.
Properties are listed below.
Compound XLIII - Anal. Calcd for C22H27NO3' 0.083 H20: C, 74.44, H, 7.73, N, 3.95 Found: C, 73.96, H, 7.73, N, 4.26. 1H NMR (300MHs, DMSO-d6): 6 12.71 (1H,s), 8.2 (1H,q), 7.1 (9H,m), 4.4 (1H,m), 3.6 (1H,m), 3.0 (1H,m), 2.85 (1H,m), 2.4 (1H,q), 1.8 (1H,m), 1.3 (2H,d), 1.15 (1H,d), 0.85 (6H,d) Comgound XLIV - Anal. Calcd for C22H17NO4F2: C, 66.49, H, 4.32, N, 3.53 Found: C, 66.14, H, 4.29, N, 3.33. ' H NMR (300MHz, DMSO-d6): d 8.05 (1 H,s), 7.5(2H,m), 7.35 (1 H,m), 7.2(7H,m), 7.0 (1 H,d), 4.7 (1 H,m), 3.2 (1 H, dd), 3.05 (1 H, m) Example 4 Compound XXXII was prepared as follows:
1-oxaspiro(2.5)octane (3.76 g, 33.48 mmol, 1.2 equiv.) and aluminum chloride (0.36 g, 2.70 mmol, 0.1 equiv.) were added to a suspension of 4-(4-aminophenyl)butyric acid (5.00 g, 27.90 mmol, 1 equiv.) in toluene (100 mL) . The mixture was refluxed under argon overnight. After being cooled to room temperature, the toluene was filtered, and the residue was washed with ethyl acetate (ca. 100mL). The combined filtrate was evaporated to yield a brown gum. The gum was dissolved with ethyl acetate (250 mL). It was then washed with water (3 x 100mL) and dried. After removal of the solvent, the residue was purified by column chromatography (30 % to 70 % ethyl acetate/hexanes), and the collected product was recrystallized from ethyl acetate-hexanes to give XXXII as yellow solid (0.8 g, 10 Properties are listed below.
'H NMR (300 MHz, DMSO-de) 6: 6.85 (2H, d, J = 8.4 Hz), 6.53 (2H, d, J = 8.4 Hz), 5.00 (1 H, br s), 2.88 (2H, s), 2.39 (2H, t, J
= 7.2 Hz), 2.15 (2H, t, J= 7.4 Hz), 1.69 (2H, m), 1.45 (10H, m). Anal. Calcd for CõH25 NO3: C, 70.07; H, 8.65; N, 4.81.
Found: C, 70.20; H, 8.69; N, 4.67.
Examp(e 5 Compound XXXIX was prepared as follows:
N-hydroxysuccinimide (7.72 g, 67.50 mmol, 1.1 equiv.) and dicyclohexylcarbodiimide (13.96 g, 67.50 mmol, 1.1 equiv.) were added to a solution of N-(2-phenylbutyryl)-4-(aminophenyl)butyric acid (20.00 g, 61.40 mmol, 1.0 equiv.) in tetrahydrofuran (400 mL). The reaction was stirred overnight at 25 C. The urea formed was removed by filtration. Glacial acetic acid (5 mL) was added to the filtrate and stirred for 2 hours. The solvent was then evaporated to yield an oil. The oil was redissolved in chloroform (300 mL), and the resultant solution was washed successively with saturated sodium bicarbonate (2 x 200 mL) and water (200 mL). The combined aqueous layers were extracted with chloroform (100 mL) to give a filtrate (a total volume of 500 mL) containing the 0-succinyl ester of N-(2-phenylbutyryl)-4-(4-aminophenyl)butyric acid.
A mixture of pheriyiglycine 0-methylester hydrochloride (12.40 g, 61.40 mmol, 1.0 equiv.) and triethylamine (35 mL) in chloroform (100 mL) was charged to an addition funnel. The mixture was added dropwise to the chloroform solution of the Osu ester prepared above. The reaction was stirred at 25 C for 24 h. The resulting solution was washed with aqueous hydrochloric acid (2 x 500 mL) and water (500 mL). The aqueous layer was back extracted with chloroform (50 mL). The combined chloroform layers were dried and evaporated to yield an oil. Aqueous sodium hydroxide (2M, 200mL) was added to the oil, and the mixture was heated to 100 C for 2 h. After being cooled to room termerature, the solution was acidified with hydrochloric acid (2 M) to pH
2.5. The precipitate was filtered, washed with hydrochloric acid (100 mL) and water (100mL) to give XXXIX as an off white solid (15.2 g, 54%).
Properties are listed below.
' H NMR (300MHz, DMSO-dg) d: 12.70 (1 H, br s), 10.00 (1 H, s), 8.55 (1 H, d), 7.50 (2H, d), 7.33 (10H, m), 7.06 (2H, d), 5.32 (1 H, d), 3.54 (1 H, m), 2.49 (2H, overlapped with DMSO), 2.16 (2H, m), 2.05 (1 H, m), 1.73 (3H, m). 0.83 (3H, t). Anal. Calcd for C2$H30N204: C, 73.30; H, 6.61; N, 5.73; Found: C, 72.54; H, 6.60; N, 5.73.
Example 6-/n Vivo Evaluation of Interferon in Rats Dosing compositions were prepared by mixing the modified amino acid compounds and interferon a2 as listed in Table 1 below in a Trizma hydrochloride buffer solution (Tris-Hcl) at a pH of about 7-8. Propylene glycol (0-25%) was added as a solubilizing agent, if necessary.
Rats were orally or intraduodenaGiy (ID) administered the dosing compositions, and delivery was evaluated by an ELISA assay for human interferon a-2b.
Results are illustrated in Table 1 below.
Oral Delivery of Interferon Carrier Carrier Dose Interferon Dose Mean Peak Serum Levels (mg/kg) (/ag/kg) of Interferon (ng/mL) XXVI 300 1000 6710 +/- 6658 5 XXXVII 160 1000 1025 +/- 276 XXVII 300 1000 3642 +/- 5895 XXXIV 400 1000 11341 +/- 8793 400 500 565 +/-515 XXXIV (ID) 400 100 1775 +/- 1023 10 XXIX 600 100 3510 +/- 2171 I 300 1000 10072 +/-3790 I(ID) 250 50 843 +/- 669 I 80 250 1369 +/-1164 VI 300 1000 8213 +/- 3077 15 VI 600 1000 8428 +/- 5001 VI (ID) 1000 15469 +/- 6712 XXXVI 400 1000 43961 +/- 14910 XIV 800 1000 5518 +/- 2718 VI I 600 1000 5568 +/- 3771 20 XXVII 300 1000 41966 +/- 19688 VIII 300 1000 1753 +/- 1529 XVIII 300 1000 19809 +/- 26107 XXX 300 1000 3910 +/- 3221 XL 300 1000 12661 +/-10933 25 none 0 1000 688 +/-173 Example 7-/n Vivo Evaluation of Salmon Calcitonin in Rats Dosing compositions were prepared and dosed using the modified amino acid compound carriers and salmon calcintonin as listed in Table 2 below.
30 The concentration of calcitonin in each composition was 2.5 Ng/ml. Each rat was administered 2 mi/kg of dosing composition.
Blood samples were collected serially from the tail artery. Serum calcium was determined by testing with a Calcium Keto (Sigma Chemical Co. -St. Louis, MO.) Results are illustrated in Table 2 below.
Example 8 - In Vivo Evaluation of Salmon Concentration in Rats A dosing composition was prepared using 400 mg of compound VI
with 2.9 ml of 25% aqueous propylene glycol. The resultant solution was stirred, and the pH was adjusted to 7.2 with sodium hydrochloride (1.01N).
Water was added to bring the total volume to 2.0 ml and a final modified amino acid concentration of 200 mg/mi. Salmon calcitonin (10 mg) was added.
This composition was dosed as described in Example 7 above.
Results are illustrated in Table 2 below.
Oral Delivery of Calcitonin Carrier Carrier Dose Dose Drug Mean Peak Serum Levels (mg/kg) (pg/kg) of calcitonin(ng/mL) XXVI 10 300 -18 +/- 6 XXVIII 10 200 -14 +/- 6 1 10 200 -16 + /- 8 VII 10 200 -13 +/- 8 VI 10 200 -29 + /- 14 10 -13 +/- 4 10 30 -24 + /- 9 Example 9 In Vivo Evaluation of Recombinant Human Growth Hormone (rhGh) in Rats Dosing compositions were prepared with modified amino acids in a phosphate buffer at a pH of about 7-8 and rhGH as listed in Table 3 below.
Rats were administered the compositions by oral gavage, intraduodenal administration (ID), or colonic administration (IC).
Results are illustrated in Table 3 below.
Oral Delivery of rhGH
Carrier Carrier Dose Dose Drug Mean Peak Serum Levels (mg/mL) (mg/mL) of rhGH (ng/mL) XXVI 500 6 -127 +/- 40 XXVII 500 6 -64 +/- 7 VI 150 6 -33 +/- 13 VI (ID) 200 3 -103 +/-85 VI (IC) 50 1.5 -98 +/- 19 II 400 6 55 +/-36 XXX 400 6 66 +/-37 XLV 400 6 28 +/- 9 IV 300 6 42 +/- 29 XLI I I 300 6 63 +/- 45 X 250 6 37 +/- 12 XXXI I 200 6 44 +/- 36 none 0 6- 1 <10 Example 10 -/n Vivo Evaluation of Heparin in Rats 900 mg of modified amino acid were dissolved in 3 mi of propylene glycol, and 0.299 gram of sodium heparin was dissolved in 3 ml of water. The two solutions were mixed by vortex. Sodium hydrochloride was added to the resultant mixture until a solution was obtained. The pH was then adjusted to 7.4 0.5 with concentrated hydrochloric acid. The final solution was sonicated at 40 C for 30 minutes to yield a dosing solution.
The dosing solution was administered by oral gavage to fasted rats.
Blood samples were collected by cardiac puncture following the administration of ketamine (44 mg/kg). Heparin activity was determined by utilizing the activated partial thromboplastin time (APTT) according to the method of Henry, J. B., Clinical Diagnosis and Management by Laboratory Methods; Philadelphia, PA; WB Saunders (1979). Results are illustrated in Table 4 below.
Oral Delivery of Heparin IF Carrier Mean Peak APTT (sec) # Animals Responding XXI 166 + /- 35 5/5 IX 102 +/- 33 34/35 VI 96 +/- 29 10/10 XLI 90 + 1- 49 5/5 XXXV 73 + /- 16 4/4 VI I 52 +/-24 17/20 E-466 67 + /- 30 4/5 XX 59 +/-42 4/4 VII 58 +/-28 14/15 XLII 45 + /- 14 5/5 XXXIII 44 +/- 28 12/20 XXVI I 44 +/- 15 18/20 V 42 +/-16 4/5 111 41 +/- 18 8/10 II 41 +/-24 3/5 XXXIX 40 +/- 17 5/10 XIX 37 +/- 11 4/5 XXII 36 +/- 19 6/11 XXVIII 35 +/- 9 3/5 none 20.7 +/- 0.17 100/100 Example 11 Low molecular weight heparin was dosed according to the method of Example 10.
Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. AII
such obvious variations are within the full intended scope of the appended claims.
Claims (31)
1. A compound selected from the group consisting of and salts thereof.
2. A poly amino acid consisting of peptides or two or more amino acids linked by an ester or anhydride linkage, the polyamino acid comprising at least one compound selected from the group consisting of and salts thereof.
3. A polyamino acid as defined in claim 2, comprising a peptide.
4. A composition comprising a. an active agent; and b. a compound as defined in claim 1.
5. A composition comprising a. an active agent; and b. a compound XL of formula
6. A composition comprising a. an active agent; and b. a compound XIV of formula
7. A composition comprising a. an active agent; and b. a compound XXXV of formula
8. A composition comprising a. an active agent; and b. a poly amino acid as defined in claim 2.
9. A composition as defined in claim 8, wherein said poly amino acid comprises a peptide.
10. A composition as defined in any one of claims 4 to 7, wherein said active agent comprises a biologically active agent.
11. A composition as defined in claim 10, wherein said biologi-cally-active agent is selected from the group consisting of a peptide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
12. A composition as defined in claim 11 , wherein said biologi-cally-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), and any combination thereof.
13. A composition as defined in claim 8, wherein said active agent comprises a biologically active agent.
14. A composition as defined in claim 13, wherein said biologi-cally-active agent is selected from the group consisting of a peptide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
15. ~A composition as defined in claim 14, wherein said biologi-cally-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), and any combination thereof.
16. ~A composition as defined in claim 9, wherein said active agent comprises a biologically active agent.
17. ~A composition as defined in claim 16, wherein said biologi-cally-active agent is selected from the group consisting of a peptide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
18. ~A composition as defined in claim 17, wherein said biologi-cally-active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine (DFO), and any combination thereof.
19. ~A dosage unit form comprising (A) ~a composition according to any one of claims 4 to 7; and (B) ~(a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.
20. ~A dosage unit form according to claim 19, comprising a tablet, a capsule, or a liquid.
21. ~A dosage unit form comprising (A) a composition according to claim 8: and (B) ~(a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.
22. ~A dosage unit form according to claim 21, comprising a tablet, a capsule, or a liquid.
23. ~A dosage unit form comprising (A) ~a composition according to claim9: and (B) ~(a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.
24. ~A dosage unit form according to claim 23, comprising a tablet, a capsule, or a liquid.
25. ~Use of a composition as defined in any one of claims 4 to 7, for delivering a biologically-active agent to an animal in need of said agent.
26. ~Use of a composition as defined in claim 8, for delivering a biologically-active agent to an animal in need of said agent.
27. ~Use of a composition as defined in claim 9, for delivering a biologically-active agent to an animal in need of said agent
28. ~A method for preparing a composition, said method comprising mixing:
(A) ~at least one biologically-active agent;
(B) ~at least one compound as defined in claim 1; and (C) ~optionally a dosing vehicle.
(A) ~at least one biologically-active agent;
(B) ~at least one compound as defined in claim 1; and (C) ~optionally a dosing vehicle.
29. ~A method for preparing a composition, said method comprising mixing:
(A) ~at least one biologically-active agent;
(B) ~at least one compound XL as defined in claim 5; and (C) ~optionally a dosing vehicle.
(A) ~at least one biologically-active agent;
(B) ~at least one compound XL as defined in claim 5; and (C) ~optionally a dosing vehicle.
30. ~A method for preparing a composition, said method comprising mixing:
(A) ~at least one biologically-active agent;
(B) ~at least one poly amino acid as defined in claim 2; and (C) ~optionally a dosing vehicle .
(A) ~at least one biologically-active agent;
(B) ~at least one poly amino acid as defined in claim 2; and (C) ~optionally a dosing vehicle .
31. ~A method for preparing a composition, said method comprising mixing:
(A) ~at least one biologically-active agent;
(B) ~at least one peptide as defined in claim 3; and (C) ~optionally a dosing vehicle.
(A) ~at least one biologically-active agent;
(B) ~at least one peptide as defined in claim 3; and (C) ~optionally a dosing vehicle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/335,148 US5643957A (en) | 1993-04-22 | 1994-10-25 | Compounds and compositions for delivering active agents |
US335,148 | 1994-10-25 | ||
PCT/US1995/013527 WO1996012473A1 (en) | 1994-10-25 | 1995-10-16 | Compounds and compositions for delivering active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2203033A1 CA2203033A1 (en) | 1996-05-02 |
CA2203033C true CA2203033C (en) | 2008-07-29 |
Family
ID=23310481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002203033A Expired - Lifetime CA2203033C (en) | 1994-10-25 | 1995-10-16 | Compounds and compositions for delivering active agents |
Country Status (15)
Country | Link |
---|---|
US (3) | US5643957A (en) |
EP (1) | EP0783299B1 (en) |
JP (1) | JP4223547B2 (en) |
AT (1) | ATE249422T1 (en) |
AU (1) | AU711887B2 (en) |
BR (1) | BR9510168A (en) |
CA (1) | CA2203033C (en) |
CZ (1) | CZ122997A3 (en) |
DE (1) | DE69531741T2 (en) |
ES (1) | ES2207655T3 (en) |
FI (1) | FI971776A (en) |
HU (1) | HUT77759A (en) |
NO (1) | NO971889L (en) |
PL (1) | PL319833A1 (en) |
WO (1) | WO1996012473A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686154B2 (en) | 1997-02-07 | 2014-04-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US6344213B1 (en) | 1996-03-29 | 2002-02-05 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
US6099856A (en) | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US6916489B2 (en) * | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
US6461643B2 (en) | 1993-04-22 | 2002-10-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US20010003001A1 (en) * | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
BR9604880A (en) | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition |
US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
EP1792624A1 (en) * | 1995-03-31 | 2007-06-06 | Emisphere Technologies, Inc. | Modified amino acids and compositions comprising them for delivering active agents |
US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5750147A (en) | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
AU7072596A (en) | 1995-09-11 | 1997-04-01 | Emisphere Technologies, Inc. | Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones |
AU3828597A (en) | 1996-06-14 | 1998-01-07 | Emisphere Technologies, Inc. | Microencapsulated fragrances and method for preparation |
US6391303B1 (en) | 1996-11-18 | 2002-05-21 | Emisphere Technologies, Inc. | Methods and compositions for inducing oral tolerance in mammals |
US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
PT993831E (en) * | 1997-02-07 | 2008-02-12 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5804688A (en) | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5776888A (en) * | 1997-02-07 | 1998-07-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5990166A (en) | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
DK1093819T3 (en) * | 1997-02-07 | 2006-09-11 | Emisphere Tech Inc | Compound and preparation for administration of active agents |
US5863944A (en) * | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5962710A (en) | 1997-05-09 | 1999-10-05 | Emisphere Technologies, Inc. | Method of preparing salicyloylamino acids |
US6440929B1 (en) | 1998-07-27 | 2002-08-27 | Emisphere Technologies, Inc. | Pulmonary delivery of active agents |
NZ509238A (en) | 1998-07-27 | 2003-07-25 | Emisphere Tech Inc | Pulmonary delivery of active agents the carrier containing acylated or sulfonated amino acids |
US6991798B1 (en) | 1998-08-07 | 2006-01-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
NZ509410A (en) * | 1998-08-07 | 2003-08-29 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
CA2358463A1 (en) * | 1999-01-08 | 2000-07-13 | Virginia Commonwealth University | Polymeric delivery agents and delivery agent compounds |
US7084279B1 (en) | 1999-02-11 | 2006-08-01 | Emisphere Technologies Inc. | Oxadiazole compounds and compositions for delivering active agents |
JP4637365B2 (en) | 1999-02-26 | 2011-02-23 | エミスフェアー・テクノロジーズ・インク | Compounds and compositions for active agent delivery |
US7018654B2 (en) * | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
WO2000059863A1 (en) | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
BR0015547A (en) | 1999-11-12 | 2002-07-23 | Mi Llc | Processes to degrade a predetermined substrate, filter cake and contaminant emerging from an underground formation, to increase the flow of hydrocarbons from a well and to treat a well bore and composition for use in hydrocarbon exploration operations |
US6818594B1 (en) | 1999-11-12 | 2004-11-16 | M-I L.L.C. | Method for the triggered release of polymer-degrading agents for oil field use |
ATE387430T1 (en) * | 1999-12-16 | 2008-03-15 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS |
US7151191B2 (en) * | 2000-01-13 | 2006-12-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO2002002509A1 (en) * | 2000-06-29 | 2002-01-10 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
DE60138468D1 (en) | 2000-09-06 | 2009-06-04 | Emisphere Tech Inc | CYANOPHENOXY CARBOXYLIC ACIDS AND COMPOSITIONS FOR THE RELEASE OF ACTIVE SUBSTANCES |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US7700775B2 (en) | 2001-03-01 | 2010-04-20 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US20030225300A1 (en) * | 2001-04-19 | 2003-12-04 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US20030091627A1 (en) * | 2001-10-31 | 2003-05-15 | Vinay Sharma | Rate-controlled delivery of macrolides |
EP1461031B1 (en) | 2001-11-29 | 2016-06-29 | Emisphere Technologies, Inc. | Formulations for oral administration of cromolyn sodium |
EP1469827B1 (en) | 2002-01-09 | 2017-12-27 | Emisphere Technologies, Inc. | Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
KR101165431B1 (en) * | 2002-02-20 | 2012-07-12 | 에미스페어 테크놀로지스, 인코포레이티드 | Method for administering glp-1 molecules |
EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
WO2004056774A2 (en) * | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
BRPI0411165A (en) * | 2003-05-14 | 2006-07-11 | Emisphere Tech Inc | pharmaceutical composition, dosage unit form and methods for preparing its use |
CA2530983C (en) * | 2003-08-20 | 2012-09-25 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
WO2005019184A1 (en) * | 2003-08-20 | 2005-03-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
TWI239542B (en) * | 2003-12-26 | 2005-09-11 | Ind Tech Res Inst | Solid-state, electrolytic capacitor, fabrication method thereof, and coupling agent used therefor |
JP2005209106A (en) * | 2004-01-26 | 2005-08-04 | Nec Corp | Portable communication terminal, received e-mail management method, program and recording medium |
WO2005072061A2 (en) | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
JP2007526332A (en) * | 2004-03-02 | 2007-09-13 | ニューロジェン・コーポレーション | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogs |
BRPI0509411A (en) * | 2004-04-16 | 2007-09-04 | Emisphere Tech Inc | method for treating malignant disease, malignancy hypercalcemia and osteolytic bone metastases, mesylate salt, composition and method of administration of active agent and bisphosphonate |
US8039018B2 (en) * | 2004-05-06 | 2011-10-18 | Emisphere Technologies, Inc. | Solid dosage form of wetted heparin |
RU2530889C2 (en) * | 2004-05-14 | 2014-10-20 | Эмисфире Текнолоджис, Инк. | Compounds and formulations for active substance delivery |
AU2005249410A1 (en) * | 2004-05-14 | 2005-12-15 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
NZ551196A (en) | 2004-05-14 | 2010-08-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
BRPI0510820A (en) | 2004-05-19 | 2007-11-27 | Emisphere Tech Inc | pharmaceutical composition, unit dosage form and its uses |
US9498487B2 (en) | 2004-05-19 | 2016-11-22 | Emisphere Technologies, Inc. | Topical cromolyn formulations |
EP1773376A4 (en) | 2004-08-03 | 2009-07-01 | Emisphere Tech Inc | Antidiabetic oral insulin-biguanide combination |
CN101010305B (en) | 2004-08-20 | 2010-08-11 | 曼金德公司 | Catalysis of diketopiperazine synthesis |
PL2322180T3 (en) | 2004-08-23 | 2015-10-30 | Mannkind Corp | Diketopiperazine salts for drug delivery |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
KR101478933B1 (en) | 2004-12-28 | 2015-01-02 | 키넥스 파마슈티컬즈, 엘엘씨 | Compositions and methods of treating cell proliferation disorders |
NZ556373A (en) | 2004-12-29 | 2010-01-29 | Emisphere Tech Inc | Pharmaceutical formulations of gallium salts |
WO2006076692A1 (en) * | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
US8975227B2 (en) | 2005-07-15 | 2015-03-10 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
JP5173807B2 (en) * | 2005-08-19 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | Cyclopropyl compounds and compositions for delivering active agents |
CN104324362B (en) | 2005-09-14 | 2018-04-24 | 曼金德公司 | Method for preparation of drug based on improving affinity of the active agent to crystalline microparticle surfaces |
CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
US8927015B2 (en) * | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
ES2538254T3 (en) * | 2006-04-18 | 2015-06-18 | Emisphere Technologies, Inc. | Dialkyl Ether Administration Agents |
US8771712B2 (en) | 2006-05-09 | 2014-07-08 | Emisphere Technologies, Inc. | Topical administration of acyclovir |
EP2044005B8 (en) * | 2006-06-26 | 2012-12-05 | Warner Chilcott Company, LLC | Prolyl hydroxylase inhibitors and methods of use |
EP2040718B1 (en) * | 2006-06-28 | 2017-12-27 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
JP5564251B2 (en) | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | Biaryl compositions and methods for modulating kinase cascades |
EP2046736B1 (en) | 2006-07-27 | 2019-06-12 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
JP5564255B2 (en) | 2006-08-18 | 2014-07-30 | エミスフェアー・テクノロジーズ・インク | Synthesis of propylphenoxy ether and use as a delivery agent |
CA2662853C (en) * | 2006-08-31 | 2016-07-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
TWI457336B (en) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | Composition and methods for modulating a kinase cascade |
US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
CA2676930C (en) | 2007-02-08 | 2015-09-08 | Emisphere Technologies, Inc. | Phenylalkylcarboxylic acid delivery agents |
JP5390404B2 (en) * | 2007-02-16 | 2014-01-15 | エミスフェアー・テクノロジーズ・インク | Compounds and compositions having cyclic moieties for delivering active agents |
WO2008112706A1 (en) | 2007-03-13 | 2008-09-18 | Nutrition 21, Inc. | Methods and compositions for the sustained release of chromium |
JP5526018B2 (en) | 2007-03-21 | 2014-06-18 | エミスフェアー・テクノロジーズ・インク | Allyloxy and alkyloxybenzoic acid delivery agents |
ES2430067T3 (en) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Sewn polypeptides |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
WO2009009041A2 (en) | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
WO2011163272A1 (en) | 2010-06-21 | 2011-12-29 | Mannkind Corporation | Dry powder drug delivery system and methods |
DK2293833T3 (en) | 2008-06-13 | 2016-05-23 | Mannkind Corp | DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101628410B1 (en) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | An interactive apparatus and method for real-time profiling of inhalation efforts |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
DK2405963T3 (en) | 2009-03-11 | 2013-12-16 | Mannkind Corp | DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR |
BRPI1013154B1 (en) | 2009-06-12 | 2020-04-07 | Mannkind Corp | MICROPARTICLES OF DICETOPIPERAZINE WITH SPECIFIC SURFACE AREAS DEFINED, DRY POWDER UNDERSTANDING THE REFERRED MICROPARTICLES, METHOD FOR FORMATION OF THE REFERENCESMICROPARTICLES AND THE FORMATION OF MICROPARTYSTEMS |
EP2461803B1 (en) | 2009-08-03 | 2018-10-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
DE102009046115A1 (en) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted 3-phenylpropanoic acids and their use |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
EP2531202A4 (en) * | 2010-02-04 | 2013-07-17 | Lowell C Parsons | Use of oral heparin preparations to treat urinary tract diseases and conditions |
EP2558085B1 (en) | 2010-04-16 | 2017-08-30 | Athenex, Inc. | Compositions and methods for the prevention and treatment of cancer |
US9714238B2 (en) * | 2010-07-02 | 2017-07-25 | Allergan, Inc. | Therapeutic agents for ocular hypertension |
WO2012003145A2 (en) * | 2010-07-02 | 2012-01-05 | Allergan, Inc. | Therapeutic agents for ocular hypertension |
KR20170058446A (en) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
EA201300669A1 (en) | 2010-12-07 | 2013-11-29 | Байер Интеллектчуал Проперти Гмбх | SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION |
KR101836957B1 (en) | 2011-03-01 | 2018-03-09 | 제이디에스 테라퓨틱스, 엘엘씨 | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
SG194034A1 (en) | 2011-04-01 | 2013-11-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
TW201806968A (en) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | Peptidomimetic macrocycles |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
AU2013221433B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
AU2013221432B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
DE102012208530A1 (en) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituted piperidinoacetamides and their use |
CN108057154B (en) | 2012-07-12 | 2021-04-16 | 曼金德公司 | Dry powder drug delivery system and method |
EP2888224B1 (en) | 2012-08-23 | 2017-11-15 | Emisphere Technologies, Inc. | Phenoxy alkyl diethanolamine and diisopropanolamine compounds for delivering active agents |
SI2890680T1 (en) | 2012-08-30 | 2018-08-31 | Athenex, Inc. Conventus Building | N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein tyrosine kinase modulators |
RU2657749C2 (en) | 2012-09-21 | 2018-06-15 | Интенсити Терапьютикс, Инк | Methods of treating cancer |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
MX2015005244A (en) | 2012-11-01 | 2015-07-14 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof. |
ES2928365T3 (en) | 2013-03-15 | 2022-11-17 | Mannkind Corp | Microcrystalline diketopiperazine compositions, methods of preparation and use thereof |
EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
CN105517607A (en) | 2013-08-05 | 2016-04-20 | 曼金德公司 | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
CN112245565A (en) | 2014-09-24 | 2021-01-22 | 艾瑞朗医疗公司 | Peptidomimetic macrocycles and uses thereof |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
RU2747528C2 (en) | 2015-12-03 | 2021-05-06 | Биосайт Лтд. | Conjugate salts for cancer treatment |
BR112018011177A2 (en) | 2015-12-03 | 2018-11-21 | Biosight Ltd | cytarabine conjugates for cancer therapy |
AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
Family Cites Families (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2671451A (en) * | 1952-06-16 | 1954-03-09 | Stephen J Bolger | Remedial pill |
USRE24899E (en) * | 1953-06-30 | 1960-11-29 | Oil-containrab | |
US2828206A (en) * | 1954-02-24 | 1958-03-25 | Roseuberg Adolf | Stabilized fat-soluble vitamins and methods of making same |
US2868740A (en) * | 1954-03-25 | 1959-01-13 | Swift & Co | Method of copolymerizing acrylic or methacrylic acid with proteinaceous material and product obtained |
US2862918A (en) * | 1956-03-12 | 1958-12-02 | Glidden Co | Acylated, isolated, partially-hydrolyzed, soya protein and process |
NL108169C (en) * | 1957-01-30 | |||
US3057344A (en) * | 1957-05-21 | 1962-10-09 | Abella Carlos Alberto | Capsule for the study of the digestive tract and method of using the same |
US3016308A (en) * | 1957-08-06 | 1962-01-09 | Moore Business Forms Inc | Recording paper coated with microscopic capsules of coloring material, capsules and method of making |
US3052655A (en) * | 1958-08-01 | 1962-09-04 | Sidney W Fox | Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid |
US3076790A (en) * | 1958-08-01 | 1963-02-05 | Sidney W Fox | Method of making copolymers of amino acids containing glutamic acid |
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
FR1351358A (en) | 1958-12-22 | 1964-02-07 | Ncr Co | Process for forming impermeable coatings for particulate matter by liquid phase separation |
FR1468601A (en) | 1958-12-22 | 1967-02-10 | Ncr Co | Process for forming protective coatings for solid and liquid particles |
NL129921C (en) * | 1958-12-31 | |||
US3170802A (en) * | 1960-12-14 | 1965-02-23 | Zh Noda Sangyo Kagaku Kenkyush | Method for treatment of soybean proteins |
GB1075952A (en) | 1962-12-31 | 1967-07-19 | Gelatine And Glue Res Ass | Microscopic capsules and methods of making them |
US3748277A (en) * | 1965-10-14 | 1973-07-24 | Ncr Co | Process of forming minute capsules |
US3474777A (en) * | 1966-02-10 | 1969-10-28 | Amp Inc | Method of administering therapeutic agents |
US3576758A (en) * | 1966-10-17 | 1971-04-27 | Ncr Co | Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds |
FR7981M (en) * | 1967-10-21 | 1970-06-08 | ||
US3491093A (en) * | 1967-11-29 | 1970-01-20 | Endo Lab | Derivatives of 5 aminomethyl-4,5,6,7-tetrahydro-4-oxoindoles |
US3565559A (en) * | 1968-03-11 | 1971-02-23 | Sumitomo Chemical Co | Process for making microcapsules |
US3574832A (en) * | 1968-05-29 | 1971-04-13 | American Cyanamid Co | Therapeutic heparin-surfactant compositions |
GB1236885A (en) | 1968-09-28 | 1971-06-23 | Fuji Photo Film Co Ltd | Method of making multi-wall capsules |
US3567650A (en) * | 1969-02-14 | 1971-03-02 | Ncr Co | Method of making microscopic capsules |
US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
US3725113A (en) * | 1970-12-17 | 1973-04-03 | Research Corp | Blood compatible microencapsulated detoxicants and method for making |
US3822348A (en) * | 1970-12-28 | 1974-07-02 | Toyo Jozo Kk | Hormone-like substance having serum calcium reducing property |
US3962416A (en) * | 1971-01-25 | 1976-06-08 | Sol Katzen | Preserved nutrients and products |
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US3794561A (en) * | 1971-09-30 | 1974-02-26 | Sasaki T | Biologically active peptide and method of preparing the same |
US3933873A (en) * | 1971-12-08 | 1976-01-20 | Texaco Inc. | Preparation of omega-aminoalkanoic acids |
US3816404A (en) * | 1971-12-08 | 1974-06-11 | Texaco Inc | Preparation of caprolactam |
US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
JPS5210427B2 (en) * | 1972-07-19 | 1977-03-24 | ||
US4351337A (en) * | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US4450150A (en) * | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
CA1045977A (en) | 1973-05-17 | 1979-01-09 | Arthur D. Little | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
DE2343037A1 (en) | 1973-08-25 | 1975-03-06 | Hoechst Ag | MEDICINAL PRODUCTS WITH ANTIDEPRESSIVE EFFECT |
US3939253A (en) * | 1973-11-02 | 1976-02-17 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease |
GB1459488A (en) * | 1974-03-19 | 1976-12-22 | Wyeth John & Brother Ltd | Piperazinedione derivatives |
US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
DK140801B (en) | 1975-01-15 | 1979-11-19 | Nordisk Insulinlab | Process for the preparation of a stable long-acting insulin preparation. |
US4183849A (en) * | 1975-01-15 | 1980-01-15 | Nordisk Insulinlaboratorium | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect |
US4048268A (en) * | 1975-02-19 | 1977-09-13 | Eli Lilly And Company | Stabilization method |
US4035507A (en) * | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
CA1077842A (en) * | 1975-10-09 | 1980-05-20 | Minnesota Mining And Manufacturing Company | Albumin medicament carrier system |
US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
US4117801A (en) * | 1976-06-10 | 1978-10-03 | Eastman Kodak Company | Apparatus for spray coating discrete particles |
FR2374910A1 (en) * | 1976-10-23 | 1978-07-21 | Choay Sa | PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS |
US4357259A (en) * | 1977-08-01 | 1982-11-02 | Northwestern University | Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres |
US4217370A (en) * | 1977-08-25 | 1980-08-12 | Blue Wing Corporation | Lipid-containing feed supplements and foodstuffs |
US4199561A (en) * | 1979-02-26 | 1980-04-22 | The Dow Chemical Company | Coated nutrients and medicaments for veterinary use |
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4345588A (en) * | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
US4239635A (en) * | 1979-06-11 | 1980-12-16 | Cincinnati Milacron Inc. | Novel diamide and lubricants containing same |
US4272506A (en) * | 1979-08-31 | 1981-06-09 | Syva Company | Purification of reagents by disulfide immobilization |
HU181009B (en) * | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group |
NZ196349A (en) * | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
IT1148784B (en) * | 1980-04-09 | 1986-12-03 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE |
DE3016170A1 (en) * | 1980-04-26 | 1981-10-29 | Bayer Ag, 5090 Leverkusen | MICROCAPSULES WITH A DEFINED OPENING TEMPERATURE, METHOD FOR THE PRODUCTION AND USE THEREOF |
CA1155853A (en) * | 1980-06-06 | 1983-10-25 | Joseph A. Martin | Imidazole derivatives and preparation thereof |
US4289759A (en) * | 1980-06-23 | 1981-09-15 | Ortho Pharmaceutical Corporation | Immunoregulatory diketopiperazine compounds |
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US4442090A (en) * | 1980-11-09 | 1984-04-10 | Kyoto Yakuhin Kogyo Kabushiki Kaisha | Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use |
US4900730A (en) * | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
GB2092136B (en) * | 1981-01-17 | 1985-06-05 | Mitsui Toatsu Chemicals | Production of n-substituted amide compounds |
US4483807A (en) | 1981-01-27 | 1984-11-20 | Japan Atomic Energy Research Institute | Process for producing a slow release composite |
JPS58140026A (en) * | 1982-01-14 | 1983-08-19 | Toyo Jozo Co Ltd | Pharmaceutical having improved absorbability |
CA1188987A (en) | 1981-03-06 | 1985-06-18 | Masataka Morishita | Preparation having excellent absorption property |
NZ201010A (en) | 1981-06-19 | 1986-02-21 | Ciba Geigy Ag | The treatment of inflammation diseases using desferrioxamine |
US4446138A (en) * | 1982-02-10 | 1984-05-01 | Pack Howard M | Method and composition for reducing weight |
CA1241646A (en) * | 1982-02-22 | 1988-09-06 | Adolfo J. De Bold | Atrial natriuretic factor |
AU567693B2 (en) | 1982-09-30 | 1987-12-03 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4393192A (en) * | 1982-12-21 | 1983-07-12 | The Standard Oil Company | Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol |
US4473620A (en) * | 1982-12-23 | 1984-09-25 | Eastman Kodak Company | Encapsulated butylated hydroxyanisole |
US4886663A (en) * | 1983-01-03 | 1989-12-12 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof |
JPS59163313A (en) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
CA1196862A (en) * | 1983-06-01 | 1985-11-19 | Anthony M.F. Sun | Microencapsulation of living tissue and cells |
CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
US4462839A (en) * | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4608278A (en) * | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
JPS60125245A (en) * | 1983-12-12 | 1985-07-04 | Nitto Electric Ind Co Ltd | Preparation of microcapsule containing liquid active substance |
US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
US4590265A (en) * | 1984-02-17 | 1986-05-20 | Eastman Kodak Company | Carboxylated cellulose ester and manufacture thereof |
JPS60176549A (en) * | 1984-02-22 | 1985-09-10 | Nisshin Oil Mills Ltd:The | Preparation of protein hydrolyzate |
US4703042A (en) * | 1984-05-21 | 1987-10-27 | Bodor Nicholas S | Orally active heparin salts containing multivalent cationic units |
FR2565102B1 (en) | 1984-06-05 | 1987-03-20 | Paris Sud Universite | BIODEGRADABLE MICROCAPSULES BASED ON SERUMALBUMIN, THEIR PREPARATION AND THEIR APPLICATION TO THE IN SITU RELEASE OF MEDICUMENTS |
US4757066A (en) * | 1984-10-15 | 1988-07-12 | Sankyo Company Limited | Composition containing a penem or carbapenem antibiotic and the use of the same |
IT1177384B (en) * | 1984-12-12 | 1987-08-26 | Boeehringer Biochemia Robin Sp | DIETARY GRANULAR PRODUCTS BASED ON AMINO ACIDS AND PROCEDURE FOR THEIR PREPARATION |
US4708952A (en) * | 1985-02-06 | 1987-11-24 | Aida Salatinjants | Method of treatment of the infectious and viral diseases by one time interference |
CS254355B1 (en) * | 1985-04-10 | 1988-01-15 | Vladimir Saudek | Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances |
US4908233A (en) * | 1985-05-08 | 1990-03-13 | Lion Corporation | Production of microcapsules by simple coacervation |
US4757024A (en) * | 1985-05-31 | 1988-07-12 | Biostar Medical Products, Inc. | Immune complex detection method and article using immunologically non-specific immunoglobulins |
US4897444A (en) * | 1985-05-31 | 1990-01-30 | The Research Foundation Of The State University Of New York | Immobilized fluorogenic substrates for enzymes; and processes for their preparation |
US4789734A (en) * | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
IT1214629B (en) * | 1985-08-29 | 1990-01-18 | Formenti Farmaceutici Spa | MICRO-ENCAPSULATION PROCEDURE OF A MEDICATION, MEDICATION SO PREPARED, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT |
ES2039203T3 (en) * | 1985-11-22 | 1993-09-16 | Takeda Chemical Industries, Ltd. | COMPOSITION OF LIPOSOMES. |
US4689182A (en) * | 1985-12-20 | 1987-08-25 | Warner-Lambert Company | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity |
LU86258A1 (en) * | 1986-01-21 | 1987-09-03 | Rech Dermatologiques C I R D S | BENZAMIDO AROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS |
IT1188550B (en) * | 1986-02-07 | 1988-01-14 | Sclavo Spa | SYNTHETIC PEPTIDE WITH INTERLEUKINA 1 HUMAN ACTIVITY |
US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
US4692284A (en) * | 1986-04-30 | 1987-09-08 | Damon Biotech, Inc. | Method and apparatus for forming droplets and microcapsules |
WO1988001165A1 (en) | 1986-08-11 | 1988-02-25 | Innovata Biomed Limited | Pharmaceutical formulations comprising microcapsules |
US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
EP0545913B1 (en) * | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
CH668257A5 (en) | 1986-09-23 | 1988-12-15 | Moeller Willi Fa | DICARBONIC ACID DIAMOND, THESE CONTAINING ION SELECTIVE MEMBRANES AND TEST DEVICES, AND LITHIUM COMPLEXES OF DICARBONIC ACID DIAMOND. |
DE3700128A1 (en) * | 1987-01-03 | 1988-07-14 | Hoechst Ag | BIODEGRADABLE POLY- (HYDROXYALKYL) - AMINODICARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR DEPOT PREPARATIONS WITH CONTROLLED ACTIVE SUBSTANCE DELIVERY |
US5077278A (en) * | 1987-01-23 | 1991-12-31 | Pfizer Inc. | Non-natural demethylavermectins compositions and method of use |
US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
MX12394A (en) | 1987-07-23 | 1993-12-01 | Ciba Geigy Ag | PROCEDURE FOR OBTAINING POLYETHYLENE GLYCOL CARBAMATES. |
JPH0725725B2 (en) * | 1987-07-23 | 1995-03-22 | 保土谷化学工業株式会社 | Benzamide derivative |
US4895725A (en) * | 1987-08-24 | 1990-01-23 | Clinical Technologies Associates, Inc. | Microencapsulation of fish oil |
US5067961A (en) * | 1988-02-18 | 1991-11-26 | Autogenesis Technologies, Inc. | Non-biodegradable two phase corneal implant and method for preparing same |
JP2670680B2 (en) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | Polylactic acid microspheres containing physiologically active substance and method for producing the same |
US5055300A (en) * | 1988-06-17 | 1991-10-08 | Basic Bio Systems, Inc. | Time release protein |
FR2636238B1 (en) * | 1988-09-14 | 1994-01-21 | Morelle Jean | NEW ANTISUDORAL COMPOSITIONS |
GB8822857D0 (en) | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
GB8823731D0 (en) | 1988-10-10 | 1988-11-16 | Smith Kline French Lab | Biologically active compounds |
US5039481A (en) * | 1988-12-16 | 1991-08-13 | Clean Air, Inc. | Aliphatic polycarboxylic acids as air purification compositions |
US4976968A (en) * | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
US4983402A (en) * | 1989-02-24 | 1991-01-08 | Clinical Technologies Associates, Inc. | Orally administerable ANF |
CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
US5122367A (en) * | 1989-03-31 | 1992-06-16 | Massachusetts Institute Of Technology | Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone |
US4963364A (en) * | 1989-04-10 | 1990-10-16 | Fox Sidney W | Microencapsulated antitumor agent |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5100918A (en) * | 1989-05-25 | 1992-03-31 | Sterling Drug, Inc. | Prevention or treatment of sunburn using the S(+) isomer of ibuprofen |
US4996292A (en) * | 1989-06-30 | 1991-02-26 | Fox Sidney W | Self-sealing artificial skin comprising copoly-alpha-amino acid |
JP2911496B2 (en) | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | Highly absorbable vaginal agent containing bioactive polypeptide |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5216124A (en) | 1989-12-15 | 1993-06-01 | G. D. Searle & Co. | Substituted cyclic tetrapeptides |
US5389377A (en) | 1989-12-22 | 1995-02-14 | Molecular Bioquest, Inc. | Solid care therapeutic compositions and methods for making same |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
FR2658076B1 (en) * | 1990-02-12 | 1992-06-12 | Sanofi Sa | COSMETIC COMPOSITION CONTAINING COPOLYMERS OF AMINO ACIDS, USEFUL AS A MOISTURIZING AGENT. |
JPH05268986A (en) | 1990-03-19 | 1993-10-19 | Bristol Myers Squibb Co | Monoclonal antibody and activation of lymphocyte |
JP3249147B2 (en) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
US5447728A (en) | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
JPH05239021A (en) | 1990-09-04 | 1993-09-17 | Microbial Chem Res Found | New actinonin derivative |
US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
DE4033419A1 (en) * | 1990-10-20 | 1992-04-23 | Wolman Gmbh Dr | POLYMOUS NITROGEN COMPOUNDS AND METAL FIXING SAEURS CONTAINING WOOD PROTECTION AGENTS |
US5271934A (en) | 1990-10-22 | 1993-12-21 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
US5137892A (en) * | 1990-12-12 | 1992-08-11 | Abbott Laboratories | Quinoline, naphthyridine and pyridobenzoxazine derivatives |
US5244653A (en) | 1991-05-01 | 1993-09-14 | Isp Chemicals Inc. | Glycine anhydride dimethylol as a biocide and preservative |
US5250236A (en) | 1991-08-05 | 1993-10-05 | Gasco Maria R | Method for producing solid lipid microspheres having a narrow size distribution |
ZA93929B (en) | 1992-02-18 | 1993-09-10 | Akzo Nv | A process for the preparation of biologically active materialcontaining polymeric microcapsules. |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US5310535A (en) | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
HU211995B (en) | 1992-06-30 | 1996-01-29 | Gyogyszerkutato Intezet | Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them |
US5401516A (en) | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
IL109403A0 (en) * | 1993-04-22 | 1994-07-31 | Emisphere Tech Inc | Oral drug delivery compositions and methods |
DE69413590D1 (en) | 1993-04-23 | 1998-11-05 | Rhone Poulenc Chimie | Polyanhydroaspartic acid and its biodegradable hydrolysis products |
-
1994
- 1994-10-25 US US08/335,148 patent/US5643957A/en not_active Expired - Lifetime
-
1995
- 1995-10-16 DE DE69531741T patent/DE69531741T2/en not_active Expired - Lifetime
- 1995-10-16 PL PL95319833A patent/PL319833A1/en unknown
- 1995-10-16 AT AT95937558T patent/ATE249422T1/en not_active IP Right Cessation
- 1995-10-16 WO PCT/US1995/013527 patent/WO1996012473A1/en active IP Right Grant
- 1995-10-16 HU HU9800903A patent/HUT77759A/en unknown
- 1995-10-16 CA CA002203033A patent/CA2203033C/en not_active Expired - Lifetime
- 1995-10-16 BR BR9510168A patent/BR9510168A/en not_active Application Discontinuation
- 1995-10-16 CZ CZ971229A patent/CZ122997A3/en unknown
- 1995-10-16 EP EP95937558A patent/EP0783299B1/en not_active Expired - Lifetime
- 1995-10-16 ES ES95937558T patent/ES2207655T3/en not_active Expired - Lifetime
- 1995-10-16 JP JP51406296A patent/JP4223547B2/en not_active Expired - Lifetime
- 1995-10-16 AU AU39633/95A patent/AU711887B2/en not_active Ceased
-
1997
- 1997-02-06 US US08/795,833 patent/US5955503A/en not_active Expired - Lifetime
- 1997-02-06 US US08/795,837 patent/US6100298A/en not_active Expired - Fee Related
- 1997-04-24 NO NO971889A patent/NO971889L/en unknown
- 1997-04-25 FI FI971776A patent/FI971776A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686154B2 (en) | 1997-02-07 | 2014-04-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
Also Published As
Publication number | Publication date |
---|---|
JP4223547B2 (en) | 2009-02-12 |
AU3963395A (en) | 1996-05-15 |
CZ122997A3 (en) | 1997-10-15 |
US5643957A (en) | 1997-07-01 |
PL319833A1 (en) | 1997-09-01 |
HUT77759A (en) | 1998-07-28 |
DE69531741T2 (en) | 2004-03-25 |
WO1996012473A1 (en) | 1996-05-02 |
BR9510168A (en) | 1997-10-14 |
JPH10507762A (en) | 1998-07-28 |
MX9702899A (en) | 1997-07-31 |
ATE249422T1 (en) | 2003-09-15 |
EP0783299A1 (en) | 1997-07-16 |
FI971776A0 (en) | 1997-04-25 |
ES2207655T3 (en) | 2004-06-01 |
DE69531741D1 (en) | 2003-10-16 |
NO971889D0 (en) | 1997-04-24 |
US5955503A (en) | 1999-09-21 |
US6100298A (en) | 2000-08-08 |
NO971889L (en) | 1997-06-23 |
EP0783299A4 (en) | 1999-06-30 |
FI971776A (en) | 1997-04-25 |
AU711887B2 (en) | 1999-10-21 |
CA2203033A1 (en) | 1996-05-02 |
EP0783299B1 (en) | 2003-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2203033C (en) | Compounds and compositions for delivering active agents | |
US5650386A (en) | Compositions for oral delivery of active agents | |
US6071510A (en) | Modified amino acids and compositions comprising the same for delivering active agents | |
EP1025840B1 (en) | Oral drug compositions | |
US6663887B2 (en) | Compounds and compositions for delivering active agents | |
US6461643B2 (en) | Oral drug delivery compositions and methods | |
US6180140B1 (en) | Modified amino acids for drug delivery | |
AU727068B2 (en) | Compounds and compositions for delivering active agents | |
WO1997036480A1 (en) | Compounds and compositions for delivering active agents | |
JP2001513080A (en) | Compositions for delivering compounds and active agents | |
EP0817643B1 (en) | Compounds and compositions for delivering active agents | |
MXPA97002899A (en) | Compounds and compositions to supply acti agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20151016 |